

Award Number: W81XWH-12-1-0565

TITLE: Intravesical NGF Antisense Therapy Using Lipid Nanoparticle For Interstitial Cystitis

PRINCIPAL INVESTIGATOR: Michael Chancellor

CONTRACTING ORGANIZATION: Lipella Pharmaceuticals, Inc.
Pittsburgh, PA 15208

REPORT DATE: October 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2015		2. REPORT TYPE Annual		3. DATES COVERED 30Sep2014 - 29Sep2015	
4. TITLE AND SUBTITLE Intravesical NGF Antisense Therapy Using Lipid Nanoparticle for Interstitial Cystitis				5a. CONTRACT NUMBER W81XWH-12-1-0565	
				5b. GRANT NUMBER PR110326	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Michael Chancellor, Naoki Yoshimura, Michele Gruber, David Chancellor E-Mail: Michael.chancellor@lipella.com				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Lipella Pharmaceuticals, Inc. 400 N Lexington Ave, Suite LL103 Pittsburgh, PA 15208				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating disorder characterized by persistent pelvic pain associated with bladder symptoms including urinary frequency and urgency. Previous studies have indicated that overexpression of nerve growth factor (NGF) is a important factor in the symptom development of IC/BPS. This project evaluates the feasibility of an anti-NGF bladder drug delivery system as a potential investigational drug product. The project aims include exploration, manufacture, characterization, and nonclinical animal testing of a liposome NGF-antisense formulation targeting IC/BPS. During the project period investigators conducted nonclinical experiments and analyzed results from an animal efficacy experiment conducted during the previous period. The project is ongoing.					
15. SUBJECT TERMS Interstitial cystitis/painful bladder syndrome (IC/PBS), Liposome					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 68	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

<u>Section</u>	<u>Page</u>
Introduction.....	2
Keywords.....	2
Overall Project Summary	2
Body.....	2
Key Research Accomplishments.....	3
Conclusion.....	8
Publications and Reportable Outcomes	8

I-1. Introduction

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating disorder characterized by persistent pelvic pain with symptoms of urinary frequency, urgency, nocturia, and painful intercourse. IC/BPS can affect both genders with epidemiological data suggesting that up to 12% of women may have early symptoms of IC/BPS. IC/BPS patients are currently treated through various means: pentosan polysulfate sodium, dimethyl sulfoxide, off label use of amitriptyline, anesthetics, immunosuppressive drugs and narcotic analgesics. Each of these approaches has significant limitations. Unfortunately, there are currently no adequate medical or surgical remedies for many IC/BPS patients. IC/BPS is recognized as a significant unmet medical need.

Previous studies indicate overexpression of nerve growth factor (NGF) as a key factor in the symptom development of IC/BPS. NGF antisense oligonucleotides hold promise for IC/BPS by restricting the effect of NGF in the bladder. However, a systemic approach for NGF silencing in the bladder risks inducing systemic adverse events, suggesting a local-bladder drug delivery approach is needed. Local delivery options have traditionally been hampered by inefficient intracellular delivery of antisense. Liposomes have been used for drug delivery in a variety of applications. The investigators have previously investigated liposome drug delivery formulations and have completed studies using intravesical liposomes to demonstrate they are not systemically absorbed.

This project explores the feasibility of liposome mediated delivery of anti-nerve growth factor (NGF) for bladder pain and frequency. Investigators are developing an investigative product, called LP-11, consisting of a liposome vehicle mixed with antisense for intravesical delivery, with LP-11's formulation under development in this project. The goal of this project is to provide the foundation for future translation of LP-11 and local NGF antisense therapies for the IC/BPS indication. Lipella Pharmaceuticals Inc is collaborating with investigators located at the University of Pittsburgh to conduct the experimental program.

I-2. Keywords

Interstitial cystitis/bladder pain syndrome (IC/BPS), nerve growth factor (NGF), Small interfering RNA (siRNA), liposome, urology, drug delivery

I-3. Overall Project Summary

In this project, investigators work to develop a local therapy targeting NGF production in the bladder for the treatment of bladder pain. Aims of this project support the preclinical investigation and early product development of LP-11. The broad aims of the project are to characterize, develop manufacturing methods, and conduct formulation development of LP-11 for future clinical trials. The project aims also include preclinical evaluation of LP-11 in experimental rat animal models. The statement of work (SOW) for the experimental plan and timeline are summarized below.

II. Body

II-1. Timeline described in the SOW

	Year 1		Year 2			Year 3		
	0-4mo	5-12mo	13-16mo	17-20mo	21-24mo	25-28mo	29-32mo	33-36mo
AIM 1	<ul style="list-style-type: none">❑ Regulatory approval for animal research❑ Obtain written approval from both IACUC and ACURO	<ul style="list-style-type: none">❑ Order animals/❑ Prepare protocols/ documentation❑ Initiate animal study and confirmation of CYP and TNBS	<ul style="list-style-type: none">❑ CYP, TNBS treatment❑ LP-NGF antisense treatment<ul style="list-style-type: none">○ Pain behavior/bladder over-activity assessment❑Tissue Analysis<ul style="list-style-type: none">○ PCR/ELISA○ Patch Clamp			Complete animal studies		Animal study data analysis/reporting
AIM 2	<ul style="list-style-type: none">❑ Optimize formulation❑ Manufacture LPs❑ Analytical method development		<ul style="list-style-type: none">❑ Develop GMP LP-NGF antisense manufacture process❑ cGMP documentation reporting❑ Manufacture GMP LP❑ Product specifications/batch release testing❑ Biosdistribution assessment			<ul style="list-style-type: none">❑ Stability Testing❑ Ex-vivo stress testing		

II-2. Research Accomplishments

Aim 1 (Year 3) Animal study data reporting

[Accomplishment-1]

Prior to this reporting period, preclinical animal studies were completed along a stepwise plan. In Aim 1 (Year 1) we concluded that cyclophosphamide (CYP) induced cystitis and trinitrobenzene sulfonic acid (TNBS) induced colitis animal models exhibited bladder hyperactivity, pain and increased expression of NGF. The results of TNBS colitis rats were published in *Neuroscience* in Year 3 (Yoshikawa et al., 2015). In Aim 1 (Year 2), we studied the therapeutic effect of LP-11 in this diseased animal model, corresponding to Aim 1's "LP-NGF antisense treatment [LP-11] Pain behavior/bladder over-activity assessment" in section II-1.

The study result was summarized in the previous period's annual report. In this period we have added additional analysis to complete the study reporting. Below is a summary of previous reported findings followed by the new analysis.

Summary of previously reported methods and results:

Purpose: The purpose of the study was to evaluate the effect of bladder delivery (intravesical) of liposome conjugated with antisense oligonucleotide (LP-11) in a rat model of IC/BPS symptoms and NGF expression induced by intracolonic 2,4,6-trinitrobenzen sulfonic acid enema (TNBS) experimental colitis.

Methods : Adult female Sprague-Dawley rats were divided into five groups (n=90); (a) control group (no TNBS and no LP-11), (b) a TNBS and LP-11 treated group, (c) a TNB treated with intravesical placebo (saline) group, (d) sham (no TNBS) and LP-11 treated group and (e) sham-saline group. Intravesical administration of .2ml of LP-11 or saline was given under isoflurane anesthesia was instilled to the bladder through an inserted urethral catheter prior to TNBS administration. Twenty-four hours after instillation of LP-11 or saline, colitis was induced by the enema of 30mg TNBS.

Ten days after LP-11 or saline injection treatments, animals were subjected to either in vivo studies or bladder tissue removal. Testing involved nociceptive behavior testing for pain, cytometry for frequency (ICI), immunohistochemistry, and polymerase chain reaction for NGF analysis.


In summarizing our findings we found: (1) in the TNBS-saline group, the score of freezing behavior, defined as a lack of movement by the rats representing bladder pain sensation, was significantly higher than that of other groups including the TNBS-LP-11 group; (2) the ICI reduction rate into the bladder is significantly higher in the TNBS-saline group than that in the TNBS-LP-11 group; (3) The mRNA and protein expression of NGF in the mucosa were significantly higher in the TNBS-saline group compared to the TNBS-LP-11 group. These finding suggest a beneficial effect of LP-11 on IC/BPS according to the measures.

Newly reported results:

Lower abdominal licking

The results for animal lower abdominal licking, corresponding to pudendal nerve-dependent pain behavior (urethral pain), was examined. In previous experiments, bilateral pelvic nerve transection significantly suppressed freezing, but not licking, behavior in rats with bladder irritation. However licking was evaluated in this study to clarify if bladder pain sensation is enhanced after chronic cystitis and if LP-11 antisense treatment suppresses bladder nociceptive responses in rats.

Licking events were counted by a blinded observer for 15 minutes in response to intravesical administration of resiniferatoxin (RTx, 0.3μM, 0.3ml) in a metabolic cage. We found the licking score in the TNBS-saline group of 80 was significantly higher than in the control group and tended to higher compare to other 3 groups including TNBS-LP-11 (Figure 1).




Protein Expression

The bladder was dissected to divide into mucosal and detrusor layers for quantification of protein of NGF. Enzyme-Linked ImmunoSorbent Assay (ELISA) was used to measure the protein expression of NGF. We observed the protein expression of NGF in the TNBS-saline group was significantly increased in the mucosa compared to control and TNBS-LP-11 groups (Figure 2). LP-11 reduced protein levels due to the direct antisense effect of reduced transport of NGF from the bladder to bladder afferent pathways in TNBS rats

Conclusions: Our overall conclusions that LP-11 had a therapeutic effect on TNBS-induced bladder hypersensitivity as evidenced reductions in licking behavior and NGF protein expression compared to placebo are unchanged given these results. Preclinical efficacy studies suggest LP-11 may be a promising treatment for IC/BPS. The results were presented at the *Military Health Research Symposium* (MHSRS) in August, 2015 (Chancellor et al, 2015) as well as in our recent review article (Ogawa et al., 2015) and submitted as an original article (Kawamorita et al., 2015) to Journal of Urology (currently under revision)..

Figure 2: NGF expression



[Accomplishment-2]

Although we showed that CYP-induced cystitis rats exhibited bladder overactivity and increased pain sensitivity (Year 1), the expression of NGF in the bladder was not always stable. Therefore, in the Year 3, we improved the model of chronic cystitis induced by intravesical application of hydrogen peroxide (HP), which showed a more stable increase in the bladder NGF level, and tested the efficacy of LP-11 treatment targeting bladder NGF upregulation in this chronic cystitis model.

Purpose: The purpose of the study was to investigate the effect of intravesical liposome-based NGF antisense (LP-11) on bladder overactivity and nociceptive behavior in a rat model of chronic cystitis induced by intravesical HP instillation.

Methods: Adult female Sprague-Dawley rats were divided into five groups (n=48); (a) saline + vehicle (SV) group, (b) saline + LP-11 group, (c) 1.5% HP + vehicle group, (d) 1.5% HP + LP-11 group. Saline or 1.5% HP was administered into the bladder on day 0. Each rat was treated with intravesical vehicle or NGF antisense administration on day 2.

Summary of Results: (1) HP-induced cystitis rats with LP-11 treatment showed significantly less bladder overactivity (cytometry) and reduced bladder-related pain behavior (freezing behavior) compared with cystitis rats without LP-11 treatment. (2) HE staining of bladder sections showed that substantial infiltration of the inflammatory cells, submucosal bleeding, and detrusor hypertrophy seen in HP-induced cystitis rats; however these histological changes were alleviated by the LP-11 treatment. (3) In RT-PCR, HP-induced cystitis rats with LP-11 treatment showed the reductions in expression of NGF and TRPV1 in the mucosa and L6-S1 dorsal root ganglia (DRG), which was increased after HP-induced cystitis.

Conclusions: These results indicate that intravesical LP-11 therapy induces a reduction in the NGF expression in the bladder mucosa and bladder afferent pathways, which results in the improvement of bladder pain behavior and frequent urination induced by hydrogen peroxide-induced chronic cystitis. Thus, intravesical LP-11 therapy could be a novel treatment that can avoid systemic adverse events for hypersensitive bladder disorders such as IC/BPS, in which NGF has been implicated as an important mediator for inducing afferent sensitization. The results were presented at 2015 *International Continence Society* (ICS) meeting in Montreal, Canada (Majima et al., 2015; ICS abstract).

Aim 2 (Year 3) Stability Testing

[Accomplishment-3]

1. Accelerated Testing of LP-11

LP-11 accelerated stability study:

DOTAP liposomal lyophilate was removed from freezer and allowed to warm to ambient temperature. A 2 mM stock solution of siRNA was made from dry siRNA powder with UltraPure Distilled Water (Invitrogen; RNAase and DNAase

free). The DOTAP lyophilate was rehydrated, and an aliquot of the siRNA solution was added to the liposome suspension to make a DOTAP and siRNA solution. The resulting mixture was shaken for approximately 30 seconds. 250 uL of the resulting solution was added to 500 uL water in a 2-mL tube, and another portion was added to 500 uL synthetic urine (Ricca Chemical Company) to bring the liposome concentration to 2 mg/mL. A sample was taken from each for baseline imaging. Each sample was placed in a water bath in an incubator at 37°C. Timing was started when the tubes were added to the incubator. Samples were taken for imaging at 30, 60, 90, 120, 180, and 240 minutes. Samples were diluted in their respective solvents for imaging. Images were sampled from three 3 uL spots on the microscope slide.

Results

For the accelerated stability study, ANOVA results indicate that there was no significant difference between treatment groups ($p=0.3517$) or for timepoints ($p=0.7355$). These results suggest that there was no significant change at any point in the size distribution of the liposomes obtained via microscopy in either urine or water solvents over the course of four hours. The following are summary statistics from the accelerated study.

Timepoint	Water		Synthetic Urine	
	Mean +/- SEM	% change	Mean +/- SEM	% change
Baseline	377 +/- 27	-	400 +/- 18	-
30 min	411 +/- 26	+9.0	430 +/- 18	+7.5
60 min	406 +/- 25	-1.2	404 +/- 17	-6.0
90 min	452 +/- 27	+11.3	396 +/- 19	-2.0
120 min	413 +/- 26	-8.6	412 +/- 17	+4.0
180 min	424 +/- 29	+2.7	378 +/- 18	-8.3
240 min	414 +/- 29	-2.4	393 +/- 18	+4.0

Discussion

Over the time period monitored in the accelerated stability study (4 hours), there was no significant change in particle area at any time point, and there was no significant difference in spot area between the water and urine preparation. This time period is longer than the proposed preparation time and bladder residence time (approx. 1 hour).

2. Long-term Stability of DOTAP liposomes LP-11 admixture

[Accomplishment]

Stability of the liposomal component of the LP-11 formulation was evaluated by testing two characteristics: DOTAP concentration and particle size.

Concentration Stability Study of DOTAP Component of LP-11:

The stability of the DOTAP component of LP-11 was evaluated by quantitative ^1H NMR analysis at specific time points following storage of the lyophilized liposomes at -20C.

Purpose

The purpose of quantitative analysis of the DOTAP component is to ensure that during storage of the lyophilized DOTAP liposomes at -20C the purity and integrity of the DOTAP is maintained. Future additional measurements will be taken of the DOTAP liposomal powder, at time points up to 8 months post manufacture, to assess long-term stability of the liposome powder at -20C storage.

Procedure

Samples were stored at -20C until analysis. At each time point analysis procedure was kept consistent: allowing first the sample vial of LP-11 liposomes to come to room temperature followed by reconstitution with USP Sterile water to a final DOTAP concentration of 7mg/mL (vials were manufactured to contain 10mg DOTAP lipid). Deuterated chloroform was added and vials were vortexed and then centrifuged to separate the aqueous and organic layers. The deuterated chloroform layer of each sample was then transferred to an NMR tube for analysis. Analysis was performed using a Bruker AVANCE III 400MHz NMR spectrometer with cryoprobe prodigy. The proton responses were calibrated with a dioleoyl phosphatidylcholine.

Results

A minimum of 4 month stability was determined for the DOTAP component of LP-11, liposomal siRNA. DOTAP concentration was determined to be consistent for the 4 month storage period at -20C freezer conditions. Quantitative results are listed in **Table 1** below. The study is ongoing full study results will be reported in the final report.

Table 1: Concentration of DOTAP in LP-11 Liposomes in mg/mL by ^1H NMR

Timepoint	Concentration (mg/mL)
1 month	6.98
2 months	
4 months	

Particle Size Stability study of DOTAP Component of LP-11:

DOTAP liposomal lyophilate sample was removed from the freezer and allowed to warm to ambient temperature. Sterile water for injection (WFI) was added to make a 2 mg/mL suspension of DOTAP. A sample from the vial was diluted to 0.2 mg/mL and three 3 μL sample spots were made on a microscope slide for imaging. This was performed at months 1, 2, 4, and the study will continue to months 6 and 8. A new vial was used at each timepoint.

Image Acquisition

All samples taken for imaging were diluted to 0.2 mg/mL liposome concentration. Images were taken with an AmScope MA1000 camera at 1280x960 resolution with 6x magnification. At least 20 images were taken at each timepoint.

Image Analysis

The purpose of the analysis is to detect changes in the liposome size distribution over time. The metric that was measured is the number of pixels per liposome spot (i.e. particle area). A program was written in the Python[[PYTHON]] programming language using the scikit-image[[SKIMAGE]] package to process the microscopy images and automatically obtain a distribution of particle areas for each image.

Error in the spot detection method has not yet been quantitatively measured (i.e. against ground-truth images); however, qualitative testing was performed by comparing input and output images. The method is robust for our particular microscopy image and it was parameterized to keep false positives at a minimum. In-focus spot areas are slightly overestimated. This error arises mainly from the mean filter. Slightly out-of-focus spot areas are slightly underestimated. This is because the peak maxima are not at the very edge of the spots but are offset from the edge closer to the center. This is reasonable, because the liposome image grows when it is slightly out-of-focus. Very out-of-focus spots are excluded via the chosen threshold. These biases are consistent throughout the samples that were taken. Future work will seek to reduce or eliminate the overestimation errors in the in-focus spots and eliminate the slightly out-of-focus spots from analysis.




Figure 3

Example Input and Results from Spot Identification Program. A) Original microscopy image of liposomes. B) Sobel-filter of (A). C) Mean-filter of (B). D) Threshold of (C). White areas are “True” and black areas are “False.”

Statistical Analysis

One-way ANOVA was performed on spot size data from the accelerated stability study. Both solvent (urine v. water) and timepoints (baseline thru 240 min) were used as model effects. As the results of the ANOVA suggested there were no significant differences, post-hoc tests were not performed.

The α -level for all tests was chosen to be 0.05. Results are reported as mean spot area \pm Standard Error of the Mean (SEM).

The ANOVA test suggested that spot size changed significantly as time from manufacture increased ($p=0.0053$). Results for mean spot areas and Tukey’s HSD test are as follows:

Comparison	p-value, Tukey’s HSD	% change
Month 1 vs. Month 2	0.1413	-11.1
Month 2 vs. Month 4	0.6570	-5.0
Month 1 vs. Month 4	0.0035*	-15.6

Timepoint	Mean Pixel Area \pm SEM
Month 1	449 \pm 17
Month 2	399 \pm 19
Month 4	379 \pm 13

These results suggest that there was a significant decrease in spot sizes from month 1 to month 4. However, there was no significant difference in mean spot size between months 1 and 2 and months 2 and 4.

Discussion

The long-term data suggest that there is a significant decrease in the mean liposome size over (at least) a four month period. Different vials were used at each timepoint. It is unlikely that the differences seen were due to variability between sample vials. Past experiments (in house; unpublished) with sphingomyelin liposomes showed no variability between liposome vials, but these experiments have not yet been performed for DOTAP liposomes.

Aim 2 (Year 3) Ex-vivo stress testing

[Accomplishment-4]

Stress testing was performed to characterize stability of LP-11 liposomes in a bladder environment.

Stress Stability Experiment

Purpose

The purpose of the *ex-vivo* stress testing was to evaluate the stability of the LP-11 liposomes in a simulated bladder environment since the product is intended for direct intravesical administration and would thus be subject to the chemical environment of the urinary bladder.

Procedure

Two critical product characteristics of the LP-11 liposomes were evaluated following exposure to the simulated bladder environment: particle size and DOTAP concentration. The testing procedure for each of these characteristics was the same as the methods listed above for the long-term stability evaluations. Vials were manufactured to contain 10mg DOTAP liposomes. Each vial was first reconstituted with 1.428mL USP Sterile water. The bladder-like environment was then modeled by mixing the reconstituted liposomes (7mg/mL) in a 2:1 (v/v) with synthetic urine (2.856mL) for a concentration of 2.33mg/mL. Vials were then incubated at 37C for 1 hour to mimic physiologic conditions (clinical protocol will include an instillation time of 1hour).

Results

The DOTAP component of LP-11 was determined to be consistent under “stress” stability conditions of dilution with synthetic urine and incubation at 37C for 1 hour. Quantitative results are listed in **Table 2** below. The study is ongoing full study results will be reported in the final report.

Table 2: Stress Stability Results—Concentration of DOTAP in LP-11 Liposomes in mg/mL by ¹H NMR

Timepoint	Concentration (mg/mL)
1 month	2.28
2 months	
4 months	

III. Research accomplishments

- Animal study data analysis/reporting
- Interim long-term stability testing data
- Completed stress testing in a bladder environment

V. Conclusions

During the reporting period we analyzed nonclinical animal data and conducted stability and stress testing of LP-11. Analysis of the animal data continues to demonstrate potential of LP-11 on IC/BPS symptoms in rat models. Stability and stress testing studies are ongoing and full results are anticipated during the final period (extension).

In the final period, Lipella Pharmaceuticals and the University of Pittsburgh will continue to collaborate, review LP-11 formulation and manufacturing data, and take appropriate steps to wind down the project. Additionally we will be preparing to continue LP-11’s experimental and regulatory plan following the conclusion of the project.

VI. Publications and Reportable Outcomes (Year 3)

Refereed

1. Yoshikawa, S., Kawamorita, N., Oguchi, T., Funahashi, Y., Tyagi, P., Chancellor, M.B., Yoshimura, N.: Pelvic organ cross-sensitization to enhance bladder and urethral pain behaviors in rats with experimental colitis. *Neuroscience*, 284: 422–429, 2015.
2. Ogawa, T., Ishizuka, O., Ueda, T., Tyagi, P., Chancellor, M.B., Yoshimura, N.: Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). *Expert Opinion on Emerging Drugs*, in press, 2015.
3. Kawamorita, N., Yoshikawa, S., Kashyap, M., Tyagi, P., Arai, Y., Chancellor, M.B., Yoshimura, N.: Liposome-based intravesical therapy 1 targeting nerve growth factor (ngf) ameliorates bladder hypersensitivity in rats with experimental colitis. Submitted to *Journal of Urology* (under revision).

Abstracts

1. Chancellor, M.B., Kaufman, J., Yoshimura, N., Tyagi, P., Kawamorita, N.: Liposome-based Intravesical Therapy targeting Nerve Growth Factor (NGF) ameliorates Bladder Hypersensitivity in Rats with Experimental Colitis. 2015 Military Health System Research Symposium. Poster session 3, MHSRS-15-0089. Ft. Lauderdale, FL. 8/17-20, 2015.
2. Majima, T., Tyagi, P., Dogishi, K., Kadekawa, K., Kashyap, M., Wada, N., Takai, S., Shimizu, T, Gotoh, M., Chancellor, M, Yoshimura, N.: The effect of intravesical liposome-based NGF antisense therapy on bladder overactivity and nociception in a rat model of cystitis induced by hydrogen peroxide. 45th Annual meeting of the International Continence Society, Abstract No. 234, Montreal, Canada, October 6-9, 2015.

PELVIC ORGAN CROSS-SENSITIZATION TO ENHANCE BLADDER AND URETHRAL PAIN BEHAVIORS IN RATS WITH EXPERIMENTAL COLITIS

S. YOSHIKAWA,^a N. KAWAMORITA,^a T. OGUCHI,^a
Y. FUNAHASHI,^a P. TYAGI,^a M. B. CHANCELLOR^c AND
N. YOSHIMURA^{a,b,*}

^a Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

^b Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

^c Department of Urology, William Beaumont Hospital, Royal Oak, MI, USA

Abstract—Neural cross-sensitization has been postulated as a mechanism underlying overlaps of chronic pelvic pain disorders such as bladder pain syndrome/interstitial cystitis (BPS/IC) and irritable bowel syndrome (IBS). Animals with experimental colitis have been used to study the underlying mechanisms for overlapped pelvic pain symptoms, and shown to exhibit bladder overactivity evidenced by frequent voiding; however, it has not directly been evaluated whether pain sensation derived from the lower urinary tract is enhanced in colitis models. Also, the cross-sensitization between the colon and urethra has not been studied previously. In the present study, we therefore investigated pain behaviors induced by nociceptive stimuli in the lower urinary tract and the involvement of C-fiber afferent pathways using rats with colitis induced by intracolonic application of 2,4,6-trinitrobenzenesulfonic acid (TNBS). In TNBS-induced colitis rats at 10 days, intravesical application of resiniferatoxin (RTx) induced a significantly greater number of episodes of both licking and freezing behaviors, which were reduced by capsaicin-sensitive C-fiber afferent desensitization. Histochemical studies using fluorescent dye tracers injected into the colon, bladder or urethra showed that dichotomized afferent neurons comprised 6.9–14.5% of L1, L6 and S1 dorsal root ganglion (DRG) neurons innervating the colon or the lower urinary tract. Transient receptor potential vanilloid 1 (TRPV1) mRNA expression was significantly increased in the bladder, urethra and S1 DRG in colitis rats. An increase in myeloperoxidase (MPO) activity was found in the colon, but not in the bladder or urethra after intracolonic TNBS treatment. These results indicate that TNBS-induced colitis increased pain sensitivity in the

bladder and urethra via activation of C-fiber afferent pathways due to colon-to-bladder and colon-to-urethral cross-sensitization, suggesting the contribution of pelvic organ cross-sensitization mechanisms to overlapped pain symptoms in BPS/IC and IBS. © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.

Key words: pain behavior, cross-sensitization, lower urinary tract, bladder, urethra, dorsal root ganglion (DRG).

INTRODUCTION

Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic urological disorder characterized as pelvic pain related to bladder filling, coupled with additional symptoms, such as increased urinary frequency and urgency, without proven urinary infection or other obvious pathology (Hanno et al., 2011). It is currently estimated that 3.3–7.9 million United States women 18 years old or older are suffering from BPS/IC (Berry et al., 2011). It has also been reported that over one-third of patients diagnosed with BPS/IC exhibit symptoms consistent with irritable bowel syndrome (IBS) (Alagiri et al., 1997; Novi et al., 2005), while 26–56% of patients diagnosed with IBS also have symptoms of BPS/IC (Maxton et al., 1989; Blanchard et al., 2004). In addition, BPS/IC patients often report pain in different and/or additional sites such as the urethra (Warren et al., 2008). However, the mechanisms underlying the pelvic organ cross-talk that contributes to overlapped symptoms in chronic pelvic pain syndromes such as BPS/IC, urethral pain and IBS have not been well clarified.

Previous animal studies demonstrated that 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis produced lower urinary tract dysfunction such as increased voiding frequency (Liang et al., 2007; Ustinova et al., 2007) and an increase in the firing rate of bladder afferent nerves in response to urinary bladder distension in rats (Ustinova et al., 2007). These animals showed increased expression of neuropeptides such as substance P and calcitonin gene-related peptide (Pan et al., 2010), growth factors and mast cells (Liang et al., 2007) in the bladder. Moreover, a recent report demonstrated that desensitization of the transient receptor potential vanilloid 1 (TRPV1) by intravesical application of resiniferatoxin (RTx) suppressed the

*Correspondence to: N. Yoshimura, Department of Urology, University of Pittsburgh School of Medicine, Suite 700 Kaufmann Medical Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA. Tel: +1-412-692-4137; fax: +1-412-692-4380.

E-mail address: nyos@pitt.edu (N. Yoshimura).

Abbreviations: BPS/IC, bladder pain syndrome/interstitial cystitis; DRG, dorsal root ganglion; IBS, irritable bowel syndrome; MPO, myeloperoxidase; RTx, resiniferatoxin; RT-PCR, real-time polymerase chain reaction; TNBS, 2,4,6-trinitrobenzenesulfonic acid; TRPV1, transient receptor potential vanilloid 1.

increased excitability of bladder spinal neurons in rats with acute colitis induced by intracolonic instillation with TNBS (Malykhina et al., 2013). These results suggest that intracolonic irritation can sensitize bladder afferent pathways, resulting in bladder overactivity. Also, in previous studies, pelvic pain conditions in the colitis model were assessed by the visceromotor response elicited by colorectal distension (Greenwood-Van Meerveld et al., 2005) and referred somatic hyperalgesia in the paw and/or abdominal skin regions (Cameron et al., 2008; Claudino et al., 2010). Thus, although the rat with experimental colitis has been used as an animal model of chronic pelvic pain, pain sensation derived from the bladder has not directly been evaluated in experimental colitis. In addition, the cross-talk between the colon and urethra to induce urethral pain has not been studied previously in the colitis model. Since our laboratory developed a rat model that can be used to investigate pain sensation from the bladder and urethra under the freely moving condition by monitoring pain behaviors such as freezing and licking (Saitoh et al., 2008), we investigated whether nociceptive behaviors induced by chemical stimuli in the lower urinary tract are enhanced in colitis rats. We also investigated the number of dichotomized afferent neurons that innervate both colon and bladder or both colon and urethra; as well as changes in gene expression of TRPV1 channels in dorsal root ganglia (DRG), bladder and urethral tissues.

EXPERIMENTAL PROCEDURES

Animals

Sixty-four female Sprague-Dawley rats (206–268 g) were used in this study. Rats were divided into the following groups: (1) 20 rats for behavioral testing, (2) 24 rats for mRNA measurement with real-time polymerase chain reaction (RT-PCR), (3) eight rats for a histochemical study with fluorescent dye tracers, and (4) 12 rats for MPO activity assay. We used female rats because of the higher prevalence of BPS/IC and IBS in women than in men (Clemens et al., 2007; Ito et al., 2007; Hall et al., 2008; Lovell and Ford, 2012) and the technical easiness in urethral catheterization during behavioral studies in female rats compared to male rats. All experiments were conducted in accordance with institutional guidelines and approved by the University of Pittsburgh Institutional Animal Care and Use Committee.

Induction of experimental colitis

Experimental colitis was induced as described in a previous report (Liang et al., 2007) with slight modification in the injection volume. Briefly, rats fasted for 24 h were anesthetized with isoflurane. A polyethylene catheter (PE90) was inserted from the anus and placed approximately 6 cm proximal to the anal verge, and then TNBS (50 mg/mL in 50% ethanol, 0.4 mL) was administered through the catheter and retained in the distal colon with the rats in a vertical position for several minutes. Thereafter, Surgilube® (E. Fougera & Co., Melville, NY, USA) was inserted into the anal canal to prevent the leakage of TNBS and then rats were returned to the housing facility

after the recovery from anesthesia until each assay. Control animals received the vehicle treatment with 0.4 mL of 50% ethanol. In some rats used for behavioral testing, capsaicin (total 125 mg/kg) was given subcutaneously in divided doses on two consecutive days: 25 and 50 mg/kg at a 12-h interval on the first day and 50 mg/kg on the second day, to induce desensitization of capsaicin-sensitive C-fiber afferent pathways as described in previous reports (Cheng and de Groat, 2004; Kullmann et al., 2008).

Nociceptive behavior study

The measurement of nociceptive behaviors was conducted according to the previously reported method (Saitoh et al., 2008). In brief, rats were acclimated in metabolic cages (Nalgene Co., Rochester, New York) for 3 h, and then placed in a Bollman-type restraining device (KN-326; Natsume Seisakusho, Tokyo, Japan). A polyethylene tube (PE-50; Clay Adams Division of Becton Dickinson, Parsippany, NJ, USA) was inserted into the bladder through the urethra, and residual urine was withdrawn. Thereafter, RTx (0.3 μ M), or the corresponding vehicle alone (10% ethanol, 10% Tween 80, and 80% physiological saline), was instilled into the bladder via the catheter at a volume of 0.3 mL and kept for 1 min. The transurethral catheter was then removed and rats were placed back into metabolic cages. Two types of behaviors, licking (lower abdominal licking) and freezing (motionless head-turning toward the lower abdomen), were scored for a 15-min interval that was divided into 5-s intervals. When licking or freezing occurred during each 5-s interval, it was scored as one positive event. The number of licking or freezing behavior events was summed for each of 5-min periods (0–5, 5–10 and 10–15 min) following the RTx treatment. The intravesical application of the solution (RTx or vehicle) was conducted in a blinded manner for assessors of animal behaviors.

Retrograde labeling of colon, bladder and urethral afferent neurons

Under isoflurane anesthesia, rats underwent a midline laparotomy to gain access to the pelvic organs. The distal colon (2.5–3.5 cm from the rectum) and the bladder or urethra were exposed, and 1,1'-diiodo-3,3',3',3'-tetramethylindocarbocyanine perchlorate (DiI, Invitrogen Inc., Paisley, UK; 1% w/v in methanol) was injected to 6–8 different sites of the colonic wall using a 30-G needle syringe. Additionally, Fast Blue (Polysciences Inc., Warrington, PA, USA; 1% w/v in water) was injected into 4–5 different sites of the bladder or urethral wall in order to examine the presence of DRG neurons innervating the colon and bladder or the colon and urethra, respectively. The total volume of dye injected into each organ was 25 μ L. To prevent leakage and labeling of adjacent tissues, the needle was left in place for 30 s after injection, and then a cotton swab was applied to prevent leaking. Abdominal incisions were closed with sutures and rats were returned to housing facility until each assay. The rats were post-operatively treated with ampicillin

(100 mg/kg, subcutaneously; Fort Dodge Animal Health, Fort Dodge, IA, USA) and buprenorphine (0.05 mg/kg subcutaneously; Reckitt Benckiser Pharmaceuticals, Richmond, VA, USA) twice a day for 3 days.

Histological assessment of labeled DRG cells

Ten days after the injection of dyes, rats were euthanized with pentobarbital, and DRG at Th13 to S2 levels were removed bilaterally. The specimens were embedded into OTC compound, frozen with dry ice/isopentane (2-methylbutane) and stored at -80°C until used. Serial transverse sections were cut at $10\text{-}\mu\text{m}$ thickness with a cryostat, and every fourth section was mounted on slides to avoid duplicate counting of the cells. Positively labeled cells were evaluated with an Olympus fluorescence microscope with a multiband filter set for Dil and FB. Three sections each from the right and left DRG at each level were randomly selected in a rat, and the number of dye-labeled cells per section was counted. Then, the number of dye-labeled cells in six sections per one DRG level was averaged in each rat, and the data were presented as mean \pm SEM of four rats. The percentage of dual-labeled neurons was determined as a ratio against the sum of Dil- or FB-labeled neurons (Malykhina et al., 2006; Christianson et al., 2007).

Myeloperoxidase (MPO) activity assay

MPO is an enzyme found primarily contained in neutrophils; and the measurement has been used as a quantitative index of inflammation in tissues including the colon from rats with colitis (Smith and Castro, 1978; Morris et al., 1989; Yang et al., 2008). Colon, bladder and urethral tissues were rinsed with cold phosphate-buffered saline (PBS) (pH 7.4), weighed, and were homogenized for 30 s at 4°C after addition of $200\text{ }\mu\text{L}$ radioimmunoprecipitation assay buffer (RIPA) lysis buffer (sc-24948; Santa Cruz biotechnology, CA, USA) per 10 mg of tissue and were homogenized for 30 s at 4°C . The homogenates were incubated for 30 min on ice, and then centrifuged at $10,000 \times g$ for 10 min at 4°C . The levels of MPO in the supernatants were measured by using a MPO assay ELISA Kit (HK105; Hycult biotechnology, Uden, Netherlands) according to the manufacturer's instruction. Quantification was performed by measuring absorbance at 450 nm using a microplate reader. The protein concentrations of supernatants were also measured by using BCA Protein Assay Kit (#23225; Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's instruction. The MPO concentration was standardized relative to protein levels and expressed in ng/mg total protein.

RNA isolation and RT-PCR analysis

One microgram of total RNA extracted from L6-S1 DRG, bladder or urethra tissues was reverse-transcribed into cDNA using ThermoScript™ RT-PCR system (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. Quantitative PCR was performed with an MX3000P real-time PCR system (Stratagene, La Jolla,

CA, USA) in a $25\text{ }\mu\text{L}$ volume using SYB Green PCR Master Mix (QIAGEN, Valencia, CA, USA). cDNA product was amplified by 40 cycles (denaturation at 95°C for 15 s; primer annealing for 55°C for 60 s; and elongation for 72°C for 30 s). Primers sequences used for real-time PCR were the following: 5'-AGT AAC TGC CAG GAG CTG GA-3' (forward) and 5'-GTG TCA TTC TGC CCA TTG TG-3' (reverse) for rat TRPV1 and 5'-GGC CAA AAG GGT CAT CAT CT-3' (forward) and 5'-GTG ATG GCA TGG ACT GTG GT-3' (reverse) for rat GAPDH, which is a house keeping gene used as the internal control. All primers for PCR reaction were designed based on the NCBI database sequence of rat reference mRNA and checked for specificity with BLAST software from the NCBI website; and PCR products were validated by size determination after separation on 2% agarose gel.

Drugs

TNBS, capsaicin and RTx were purchased from Sigma–Aldrich (St. Louis, MO, USA). Capsaicin and RTx were dissolved in a vehicle consisting of 10% ethanol, 10% Tween 80, and 80% physiological saline.

Statistical analysis

All data were represented as the mean \pm SEM. Statistical significance was determined by unpaired *t*-test (two-tailed) or a one-way analysis of variance (ANOVA) followed by Bonferroni's Multiple Comparison test. The *P* values < 0.05 were considered significant.

RESULTS

Nociceptive behaviors in conscious rats treated with TNBS

At day 10 after intracolonic administration of TNBS, rats did not show apparent pain behaviors such as freezing or licking compared with vehicle (for TNBS)-treated control rats when noxious stimulation was not applied (Fig. 1A, B; intravesical application of vehicle for RTx). When RTx ($0.3\text{ }\mu\text{M}$) was intravesically applied, TNBS-untreated control rats exhibited no apparent freezing behavior with slightly enhanced licking behavior only for the initial 5-min observation period. On the other hand, a significantly greater number of episodes of both licking and freezing behaviors were shown after intravesical application of RTx ($0.3\text{ }\mu\text{M}$) in rats with TNBS-induced colitis compared with the vehicle-treated group (Fig. 1C–F; $P < 0.001$, respectively), indicating increased pain sensitivity to noxious stimuli in the lower urinary tract following TNBS-induced colitis. In addition, these enhanced pain behaviors were significantly reduced with pre-treatment with capsaicin that induced desensitization of capsaicin-sensitive C-fiber afferent pathways (Fig. 1C–F; $P < 0.01$, respectively).

MPO activity

At day 10 after intracolonic application of TNBS, MPO activity in the colon was significantly ($P < 0.01$)




Fig. 1. Nociceptive behaviors, licking and freezing in rats with intracolonic administration of TNBS. (A and B) Effects of intracolonic administration of TNBS on licking (A) and freezing (B) behavior events in the absence of intravesical noxious stimulation in rats with vehicle (0.4 mL of 50% ethanol) or TNBS injection into the colon. Open and closed circles indicate behavioral events after intravesical application of vehicle (10% ethanol, 10% tween 80 and 80% saline used for dissolving RTx) in rats with intracolonic vehicle and TNBS injection, respectively. (C, D, E and F) Nociceptive behaviors induced by intravesical application of RTx in rats with intracolonic administration of TNBS. TNBS-untreated rats (vehicle for TNBS) with intravesical treatment of vehicle (intravesical vehicle for RTx) or RTx were also included as controls. After RTx (0.3 μ M) was applied intravesically for 1 min, the number of licking and freezing behavior events was counted for 15 min, and summed for every 5-min period and plotted in C and D, respectively. The total number of licking and freezing behavior events for each of 5-min periods after the instillation by RTx is shown in E and F, respectively. Some TNBS-treated rats were treated with capsaicin 4 days before the observation (capsaicin-pretreated) to investigate the effect of desensitization of capsaicin-sensitive afferent pathways. Each point or bar represents the mean \pm SEM from five or six rats. Vehicle for RTx was 10% ethanol, 10% tween 80 and 80% saline. Vehicle for TNBS was 50% ethanol. * P < 0.05; ** P < 0.01; *** P < 0.001 (two-tailed, unpaired t -test or one-way ANOVA followed by Bonferroni's Multiple Comparison test).




Fig. 2. Effects of intracolonic administration of TNBS on myeloperoxidase (MPO) activities in the colon, bladder and urethra in rats. MPO activities were quantified 10 days after the induction of colitis in rats. Each bar represents the mean \pm SEM from six rats. Sham was treated with the vehicle for TNBS (50% ethanol). ** P < 0.01 vs. the sham group (two-tailed, unpaired t -test).

increased compared with the vehicle-treated group (Fig. 2). On the other hand, there was no change in MPO activities in either the bladder or urethra in rats with TNBS-induced colitis (Fig. 2).

Distribution of afferent neurons innervating colon, bladder and urethra

DRG neurons retrogradely labeled by fluorescent dyes injected into the bladder, urethra or colon are counted in DRG sections at T13 to S2 levels. Colonic afferent neurons labeled with Dil were distributed in L1, L2, L6 and S1 DRGs with abundant labeling in L1 and S1 DRG neurons whereas bladder or urethra afferent neurons labeled by FB injected into the bladder or urethra, respectively, were distributed in L1, L6 and S1 DRGs with abundant labeling in L6 DRG neurons (Fig. 4). In T13, L3–L5 and S2 DRGs, few or no cells were labeled with either FB or Dil. Dichotomized afferent neurons innervating both colon and bladder or both colon and urethra were observed in L1, L6 and S1 DRGs (Figs. 3 and 4). When Dil and FB were injected into the colon and bladder, respectively, the ratio of afferent neurons with dichotomizing projection to both colon and bladder was 6.48–14.3% among colon or bladder-innervating afferent neurons; specifically 6.48 \pm 2.26% in L1 DRG, 14.0 \pm 2.50% in L6 DRG and 14.3 \pm 1.99% in S1 DRG




Fig. 3. Representative photomicrographs of DRG sections showing retrogradely labeled DRG neurons 10 days after the injection of Dil into the colon and FB into the bladder or urethra. Upper panels (A–C) display the fluorescent image of the same L6 DRG section showing FB-labeled bladder afferent neurons (A), Dil-labeled colon afferent neurons (B) and dichotomized afferent neurons innervating both colon and bladder indicated by yellow arrows (C). Lower panels (D–F) display the fluorescent image of the same S1 DRG section showing FB-labeled urethral afferent neurons (D), Dil-labeled colon afferent neurons (E) and dichotomized afferent neurons innervating both colon and urethra indicated by yellow arrows (F). Calibration bars = 50 μ m.




Fig. 4. Distribution of afferent neurons projected to the colon, bladder and urethra in dorsal root ganglia at the level of T3 to S2 in rats. (A) The distribution of labeled neurons after Dil and FB injection into the distal colon and bladder wall, respectively. In each bar, colonic, bladder and dually labeled afferent neurons are expressed as shown in panel A. (B) Distribution of labeled neurons after Dil and FB injection into the distal colon and urethral wall, respectively. In each bar, colonic, urethral and dually labeled afferent neurons are expressed as in panel B. At each DRG level, the number of labeled neurons was averaged in six sections (three each from light or left side) in one rat; then the data was expressed as mean \pm SEM of four rats.

expressed as percentage of Dil and FB dually labeled neurons among the sum of Dil- or FB-labeled neurons in the colon/bladder dye-injected group ($n = 4$ rats). In another series of experiments, when Dil and FB were injected into the colon and urethra, respectively, the ratio of afferent neurons with dichotomizing projection to the colon and urethra was 7.41–9.30% among colon or urethra-innervating afferent neurons; specifically $7.41 \pm 1.78\%$ in L1 DRG, $9.30 \pm 0.53\%$ in L6 DRG and $8.43 \pm 1.85\%$ in S1 DRG, expressed as percentage of Dil and FB dually labeled neurons among the sum of

Dil- or FB-labeled neurons in the colon/urethra dye-injected group ($n = 4$ rats).

Changes in TRPV1 mRNA in the DRG, bladder and urethra after TNBS treatment in rats

In TNBS-treated colitis rats, the mRNA levels of TRPV1 in the bladder, urethra and S1 DRG were significantly increased compared to sham rats (Fig. 5; $P < 0.05$, respectively).




Fig. 5. Expression levels of TRPV1 mRNA against a house keeping gene (GAPDH) in the bladder (A), urethra (B), L6 DRG (C) and S1 DRG (D) in vehicle (Sham) and TNBS-treated rats. * $P < 0.05$ vs. the sham group (two-tailed, unpaired t -test).

DISCUSSION

The results in the present study demonstrated that experimental colitis dramatically enhanced the freezing behavior induced by intravesically applied RTx (TRPV1 receptor agonist) at a low concentration (0.3 μ M), which induced only a few events of nociceptive behaviors in TNBS-untreated control rats. Freezing behavior induced by intravesical application of RTx in rats was characterized as a typical nociceptive response to activation of pelvic nerve afferents innervating the bladder (Saitoh et al., 2008). Also, our previous studies showed that the delivery of therapeutic genes encoding enkephalins or anti-inflammatory cytokines to the bladder and bladder afferent pathways using non-replicating herpes simplex virus vectors is effective to reduce freezing behavior induced by intravesical RTx administration without affecting licking behavior in rats (Funahashi et al., 2013; Oguchi et al., 2013; Yokoyama et al., 2013), indicating that RTx-induced freezing behavior represents the pain behavior derived from nociceptive stimulation of the bladder. Although previous studies demonstrated that rats with colitis induced by TNBS have frequent micturition and increased afferent excitability in response to urinary bladder distention in anesthetized rats (Ustinova et al., 2007), increased bladder pain sensitivity in this colitis model had not yet been shown. In addition, von Frey testing in the paw and/or abdominal skin regions has been used to evaluate the referred pelvic pain in rodent colitis models (Cameron et al., 2008; Claudino et al., 2010); however, it is not known how the referred somatic hyperalgesia in these regions correlates to pain sensation derived from the bladder. In this regard, our current results directly demonstrated that TNBS-induced colitis at 10 days enhances bladder pain sensation elicited by nociceptive stimuli in the bladder (i.e., freezing behavior) in rats. Furthermore, we confirmed that dichotomized

afferent neurons projecting to both the distal colon and bladder are identified in DRGs at the L1, L6 and S1 levels, the percentage of which (6.5–14.3%) is in accordance with the results in the previous reports (Malykhina et al., 2006; Christianson et al., 2007), supporting the previous notion that the existence of dichotomizing pelvic afferents could provide a pre-existing neuronal network for potential pelvic organ cross-sensitization (Ustinova et al., 2010).

Another new finding in this study is an existence of an organ cross-talk between the colon and urethra following TNBS-induced colitis because the cross-talk between these two organs has not been evaluated previously. The present study showed that dichotomization of sensory neurons projecting to the distal colon and urethra were shown at L1, L6 and S1 levels (7.4–9.3% of the sum of colon or urethral afferent neurons) in rats and that colitis rats showed significantly enhanced licking behavior after the intravesical application of RTx. Because the licking behavior induced after intravesical application of RTx was prevented by transection of the pudendal nerves that innervate the urethra, but not the bladder (Saitoh et al., 2008), it is assumed that RTx-induced licking behavior represents urethral pain due to afferent nerve activation in the pudendal nerve by RTx expelled from the bladder to the urethra during voiding. Therefore, these data suggest that the existence of dichotomizing pelvic afferents between the colon and urethra could contribute to pelvic organ cross-sensitization between these two organs to increase pain sensitivity in the urethra after colonic inflammation. Increased bladder and urethral pain sensitivity after colonic inflammation in this study may explain at least in part the frequent association of urethral pain in BPS/IC patients (Warren et al., 2008).

In this study, increased MPO activity, which correlates with the tissue neutrophil infiltration, was found in the colon, but not in the bladder or urethra, following TNBS-induced colitis. These results indicate that pain hypersensitivity of the bladder and urethra in rats with TNBS-induced colon inflammation is produced by the indirect mechanisms in the lower urinary tract other than inflammatory changes directly elicited by TNBS administered into the colon. Previous studies have demonstrated that pelvic organ cross sensitization is induced by activation of dichotomized afferents innervating different pelvic organs and that activation of nociceptive C-fiber afferents in one organ could sensitize afferent pathways in another organ to release neuropeptides such as substance P that trigger neurogenic inflammation and mast cell activation (Malykhina et al., 2012; Fitzgerald et al., 2013). Also, Pan et al. demonstrated that desensitization of TRPV1-expressing afferent pathways by intracolonic application of RTx, a TRPV1 receptor agonist, prior to the induction of colonic inflammation prevented the release of these peptides from the peripheral nerve terminals and reduced the development of neurogenic cross-talk between the colon and bladder (Pan et al., 2010). These results suggest that TRPV1-expressing C-fiber afferent pathways significantly contribute to the colon-to-bladder cross sensitization following colitis. Clinically, an increase in TRPV1

expression in the bladder has also been reported in patients with chronic pelvic pain syndromes including BPS/IC (Lowe et al., 1997; Liu et al., 2007; Akbar et al., 2008; Poli-Neto et al., 2009). In addition, previous preclinical studies demonstrated that immunohistochemical upregulation of TRPV1 in L6-S1 DRG innervating the colon was observed at 72 h after the induction of colitis with TNBS in rats (De Schepper et al., 2008). Our results also showed upregulation of TRPV1 mRNA expression in the bladder, urethra and S1 DRG as well as enhanced pain behaviors, which was reduced after desensitization of capsaicin-sensitive afferent pathways in rats with TNBS-induced colitis rats. These results further support the contribution of TRPV1-expressing C-fiber afferent pathways to both colon-to-bladder and colon-to-urethra cross sensitizations induced by colitis, which induce increased pain sensation in the bladder and urethra, respectively.

Previous studies reported that the combination rat model of endometriosis and ureteral calculosis shows enhanced pain behavior from both the urinary tract and female reproductive area, indicating that these two comorbidities strengthen the viscerovisceral cross-talk (Giamberardino et al., 2002; Lopopolo et al., 2014). Therefore, future studies using animal models including those of combination visceral pain could further clarify the underlying mechanisms and help explore new therapeutic targets for clinical symptoms in chronic pain syndromes.

CONCLUSION

We demonstrated that TNBS-induced colitis at 10 days enhances pain sensation derived from the bladder and urethra as evidenced by increased freezing and licking behaviors elicited by nociceptive bladder and urethral stimuli, respectively. These enhanced pain behaviors are considered to be due to activation of TRPV1-expressing C-fiber afferent pathways, possibly through dichotomized afferents innervating both colon and lower urinary tract. These pelvic organ cross-sensitization mechanisms could be involved in overlapped pain symptoms in BPS/IC and IBS.

CONFLICT OF INTEREST

None of the authors has any conflict of interest with any of the data presented in this manuscript.

Acknowledgements—This work was supported by grants from DOD (W81XWH-12-1-0565) and NIH (DK088836 and P01 DK093424).

REFERENCES

- Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S (2008) Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. *Gut* 57:923–929.
- Alagiri M, Chottiner S, Ratner V, Slade D, Hanno PM (1997) Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. *Urology* 49:52–57.
- Berry SH, Elliott MN, Suttrop M, Bogart LM, Stoto MA, Eggers P, Nyberg L, Clemens JQ (2011) Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. *J Urol* 186:540–544.
- Blanchard EB, Keefer L, Lackner JM, Galovski TE, Krasner S, Sykes MA (2004) The role of childhood abuse in Axis I and Axis II psychiatric disorders and medical disorders of unknown origin among irritable bowel syndrome patients. *J Psychosom Res* 56:431–436.
- Cameron DM, Brennan TJ, Gebhart GF (2008) Hind paw incision in the rat produces long-lasting colon hypersensitivity. *J Pain* 9:246–253.
- Cheng CL, de Groat WC (2004) The role of capsaicin-sensitive afferent fibers in the lower urinary tract dysfunction induced by chronic spinal cord injury in rats. *Exp Neurol* 187:445–454.
- Christianson JA, Liang R, Ustinova EE, Davis BM, Fraser MO, Pezzone MA (2007) Convergence of bladder and colon sensory innervation occurs at the primary afferent level. *Pain* 128:235–243.
- Claudino RF, Marcon R, Bento AF, Chichorro JG, Rae GA (2010) Endothelins implicated in referred mechanical hyperalgesia associated with colitis induced by TNBS in mice. *Can J Physiol Pharmacol* 88:661–667.
- Clemens JQ, Link CL, Eggers PW, Kusek JW, Nyberg Jr LM, McKinlay JB (2007) Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women. *J Urol* 177:1390–1394.
- De Schepper HU, De Winter BY, Van Nassauw L, Timmermans JP, Herman AG, Pelckmans PA, De Man JG (2008) TRPV1 receptors on unmyelinated C-fibres mediate colitis-induced sensitization of pelvic afferent nerve fibres in rats. *J Physiol* 586:5247–5258.
- Fitzgerald JJ, Ustinova E, Koronowski KB, de Groat WC, Pezzone MA (2013) Evidence for the role of mast cells in colon-bladder cross organ sensitization. *Auton Neurosci* 173:6–13.
- Funahashi Y, Oguchi T, Goins WF, Gotoh M, Tyagi P, Goss JR, Glorioso JC, Yoshimura N (2013) Herpes simplex virus vector mediated gene therapy of tumor necrosis factor- α blockade for bladder overactivity and nociception in rats. *J Urol* 189:366–373.
- Giamberardino MA, Berkley KJ, Affaitati G, Lerza R, Centurione L, Lapenna D, Vecchiet L (2002) Influence of endometriosis on pain behaviors and muscle hyperalgesia induced by a ureteral calculosis in female rats. *Pain* 95:247–257.
- Greenwood-Van Meerveld B, Johnson AC, Foreman RD, Linderth B (2005) Spinal cord stimulation attenuates visceromotor reflexes in a rat model of post-inflammatory colonic hypersensitivity. *Auton Neurosci* 122:69–76.
- Hall SA, Link CL, Pulliam SJ, Hanno PM, Eggers PW, Kusek JW, McKinlay JB (2008) The relationship of common medical conditions and medication use with symptoms of painful bladder syndrome: results from the Boston area community health survey. *J Urol* 180:593–598.
- Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer RD, Newman D, Nyberg Jr L, Payne CK, Wessellmann U, Faraday MM (2011) AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. *J Urol* 185:2162–2170.
- Ito T, Ueda T, Honma Y, Takei M (2007) Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: analysis of 282 Japanese patients. *Int J Urol* 14:1068–1070.
- Kullmann FA, Artim DE, Birder LA, de Groat WC (2008) Activation of muscarinic receptors in rat bladder sensory pathways alters reflex bladder activity. *J Neurosci* 28:1977–1987.
- Liang R, Ustinova EE, Patnam R, Fraser MO, Gutkin DW, Pezzone MA (2007) Enhanced expression of mast cell growth factor and mast cell activation in the bladder following the resolution of trinitrobenzenesulfonic acid (TNBS) colitis in female rats. *NeuroUrol Urodyn* 26:887–893.
- Liu L, Mansfield KJ, Kristiana I, Vaux KJ, Millard RJ, Burcher E (2007) The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. *NeuroUrol Urodyn* 26:433–438 [discussion 439; discussion 451–433].

- Lopopolo M, Affaitati G, Fabrizio A, Massimini F, Lapenna D, Giamberardino MA, Costantini R (2014) Effects of tramadol on viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis. *Fundam Clin Pharmacol* 28:331–341.
- Lovell RM, Ford AC (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. *Clin Gastroenterol Hepatol* 10(712–721):e714.
- Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL (1997) Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. *Br J Urol* 79:572–577.
- Malykhina AP, Qin C, Greenwood-van Meerveld B, Foreman RD, Lupu F, Akbarali HI (2006) Hyperexcitability of convergent colon and bladder dorsal root ganglion neurons after colonic inflammation: mechanism for pelvic organ cross-talk. *Neurogastroenterol Motil* 18:936–948.
- Malykhina AP, Qin C, Lei Q, Pan XQ, Greenwood-Van Meerveld B, Foreman RD (2013) Differential effects of intravesical resiniferatoxin on excitability of bladder spinal neurons upon colon-bladder cross-sensitization. *Brain Res* 1491:213–224.
- Malykhina AP, Wyndaele JJ, Andersson KE, De Wachter S, Dmochowski RR (2012) Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011. *Neurourol Urodyn* 31:352–358.
- Maxton DG, Morris JA, Whorwell PJ (1989) Ranking of symptoms by patients with the irritable bowel syndrome. *BMJ* 299:1138.
- Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL (1989) Hapten-induced model of chronic inflammation and ulceration in the rat colon. *Gastroenterology* 96:795–803.
- Novi JM, Jeronis S, Srinivas S, Srinivasan R, Morgan MA, Arya LA (2005) Risk of irritable bowel syndrome and depression in women with interstitial cystitis: a case-control study. *J Urol* 174:937–940.
- Oguchi T, Funahashi Y, Yokoyama H, Nishizawa O, Goins WF, Goss JR, Glorioso JC, Yoshimura N (2013) Effect of herpes simplex virus vector-mediated interleukin-4 gene therapy on bladder overactivity and nociception. *Gene Ther* 20:194–200.
- Pan XQ, Gonzalez JA, Chang S, Chacko S, Wein AJ, Malykhina AP (2010) Experimental colitis triggers the release of substance P and calcitonin gene-related peptide in the urinary bladder via TRPV1 signaling pathways. *Exp Neurol* 225:262–273.
- Poli-Neto OB, Filho AA, Rosa e Silva JC, Barbosa Hde F, Candido Dos Reis FJ, Nogueira AA (2009) Increased capsaicin receptor TRPV1 in the peritoneum of women with chronic pelvic pain. *Clin J Pain* 25:218–222.
- Saitoh C, Chancellor MB, de Groat WC, Yoshimura N (2008) Effects of intravesical instillation of resiniferatoxin on bladder function and nociceptive behavior in freely moving, conscious rats. *J Urol* 179:359–364.
- Smith JW, Castro GA (1978) Relation of peroxidase activity in gut mucosa to inflammation. *Am J Physiol* 234:R72–R79.
- Ustinova EE, Fraser MO, Pezzone MA (2010) Cross-talk and sensitization of bladder afferent nerves. *Neurourol Urodyn* 29:77–81.
- Ustinova EE, Gutkin DW, Pezzone MA (2007) Sensitization of pelvic nerve afferents and mast cell infiltration in the urinary bladder following chronic colonic irritation is mediated by neuropeptides. *Am J Physiol Renal Physiol* 292:F123–F130.
- Warren JW, Langenberg P, Greenberg P, Diggs C, Jacobs S, Wessellmann U (2008) Sites of pain from interstitial cystitis/painful bladder syndrome. *J Urol* 180:1373–1377.
- Yang X, Han JQ, Liu R (2008) Effects of experimental colitis on the expressions of calcitonin gene-related peptide and vanilloid receptor 1 in rat spinal cord sensory neurons. *Sheng Li Xue Bao* 60:143–148.
- Yokoyama H, Oguchi T, Goins WF, Goss JR, Nishizawa O, de Groat WC, Wolfe D, Krisky DM, Glorioso JC, Yoshimura N (2013) Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception. *Hum Gene Ther* 24:170–180.

(Accepted 26 August 2014)
(Available online 15 October 2014)

EXPERT OPINION

1. Background
2. Medical need
3. Existing treatments for IC/BPS
4. Market review
5. Current research goals
6. Scientific rationale
7. Competitive environment
8. Potential development issues
9. Conclusion
10. Expert opinion

Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS)

Teruyuki Ogawa, Osamu Ishizuka, Tomohiro Ueda, Pradeep Tyagi, Michael B Chancellor & Naoki Yoshimura[†]

[†]Department of Urology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA

Introduction: Interstitial cystitis or bladder pain syndrome (IC/BPS) is a debilitating chronic disease characterized by suprapubic pain and lower urinary tract symptoms; however, the etiology is still unknown. Therefore, the long-lasting, effective treatments of IC/BPS are still not established, and the treatment is sometimes empirically selected depending on practitioners' experience and preference.

Area covered: In this review we focus on the current treatments, ongoing clinical trials, and several potential new drugs based on the results of basic and clinical research studies. First, we discuss the potential etiologies of IC/BPS that include altered barrier lining, afferent and/or central nervous system abnormalities, possible contribution of inflammation or infection and abnormal urothelial signaling. Then, the current therapies of IC/BPS, either systemic or local, are reviewed by critical evaluation of the efficacy and shortcomings of each treatment. Finally, based on proposed etiologies of the disease, potential emerging drugs and treatments are discussed.

Expert opinion: Current therapies often fail to control the symptoms of IC/BPS. Several interventions including sustained drug release and retaining techniques, and drugs that act on afferent neural pathways are emerging and may be promising. In addition, phenotyping of IC/BPS patients based on cystoscopic findings (e.g., Hunner's vs. non-Hunner's lesion) or patients' symptoms would be important for further investigation of IC/BPS etiology and the evaluation of efficacy of new treatments.

Keywords: bladder pain syndrome, clinical trials, current research, interstitial cystitis

Expert Opin. Emerging Drugs (2015) 00(00):1-16

1. Background

1.1. Clinical findings

Hunner initially reported [1] in 1915 that there is a rare type of bladder ulcer in women, which later became known as the well-recognized disease, interstitial cystitis (IC). IC presents clinically with the characteristic changes in bladder ulcerative lesions, also known as Hunner's lesion, [2] and discriminative symptoms such as bladder pain and urinary frequency. [1,3–5] In 1988, the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) developed the criteria for IC; however, these criteria were too strict for widespread clinical use. [6] More recently, a symptom-based definition of IC/bladder pain syndrome (IC/BPS) has been developed, and the guideline was published by the American Urological Association (AUA) in 2011. [4] In the guideline, they indiscriminate subtypes based on the existence of Hunner's lesion. IC/BPS is defined in the AUA guideline as: "An unpleasant sensation (pain, pressure and/or discomfort) associated with lower urinary tract symptoms of more than six weeks duration, in the absence of



Taylor & Francis
Taylor & Francis Group

infection or other identifiable causes".[4] IC/BPS is a common disease in middle-aged and elderly women. The number of adult women patients with IC/BPS is estimated to be between 422,803 and 21,454,813 in the US.[7] It is also estimated that the medical care for IC/BPS costs more than \$11,000 per year per patient.[8]

At present, there are two major subtypes of IC/BPS: those with or without Hunner's lesion, which are also known as ulcerative or non-ulcerative IC/BPS, respectively. Although Hunner's lesion, which is a typical finding in IC/BPS during cystoscopic examination, has been considered to be a rare occasion in IC/BPS patients, it seems that the prevalence is actually higher than expected as up to 50% of IC/BPS patients reportedly have Hunner's lesion.[2,9,10] In general, symptoms between the two subtypes are quite similar, although the patients with IC/BPS with Hunner's lesion have smaller bladder capacity.[11,12] In addition, glomerulations, which are defined as multiple petechia-like hemorrhages on bladder distension, have been used as a diagnostic criterion for IC/BPS; however, the specificity of glomerulations is in question as they are seen not only in IC/BPS but also in other conditions.[11,13] The therapies for IC/BPS are often difficult and frustrating, and the severe symptoms impair the quality of life and put restrictions on social and daily life.[14] In the guideline of European Association of Urology (EAU), IC/BPS is defined as a part of chronic pelvic pain syndrome (CPPS). [9] In CPPS, modification of peripheral organs alters both the peripheral and central nervous systems (CNS), which can lower the threshold to stimuli. There are other presumed mechanisms of the CPPS, including altered pain perception of the supraspinal sites and psychological modulation.[9] Thus, the pathophysiology of CPPS, including IC/BPS, is multifactorial and a multidisciplinary approach to the management of symptoms is essential.[9]

1.2. Pathophysiology of IC/BPS

The definitive etiology of IC/BPS is not yet clear; however, the pathogenesis of IC/BPS is thought to include various factors.[15] First, a leaky urothelium with increased permeability is present in IC/BPS patients. Lilly et al. confirmed enhanced urea absorption in IC/BPS patients after intravesical administration of a urea solution.[16] Buffington et al. showed that blood fluorescein levels were higher in IC/BPS patients than controls after fluorescein was administered orally, suggesting increased absorption of the agent from the bladder surface upon excretion.[17] Previous studies have investigated the mechanisms of increased permeability. For instance, antiproliferative factor (APF), which was later characterized as a frizzled-8 related sialoglycopeptide, inhibits urothelial proliferation, thereby adversely affecting barrier function.[18,19] Also, heparin-binding epidermal growth factor, like growth factor which is known to be decreased in the IC/BPS bladder, functionally antagonizes APF activity through mitogen-activated protein kinase signaling pathways

in bladder urothelial cells.[20] Impaired tight junction proteins including ZO-1, connexin43 and connexin45 are also postulated as the factors inducing increased permeability. In cats with feline IC, urothelial release of nitric oxide (NO) is also enhanced.[23,24] In addition, altered expression of uroplakin, which covers the apical surface of urothelium, is found in IC/BPS without Hunner's lesion, suggesting that the change leads the functional property of the bladder. The impaired barrier function induced by unknown pathogenesis, which may include bacterial infection, allows the toxic substances in urine to infiltrate into the suburothelium. Then, the toxic substances are likely to stimulate bladder afferent pathways and inflammatory responses such as cytokine production to induce bladder pain and/or urinary urgency (Figure 1). In addition, there are other potential mechanisms by which chronic pelvic pain is induced in IC/BPS. Sensitization of peripheral afferent pathways due to stimulating substances and/or alterations in urothelial-afferent function lowers the threshold for sensory nerve activation in response to peripheral stimuli, resulting in pain sensation. Finally, sensitization of the CNS may be involved in the pathogenesis of IC/BPS. In the spinal cord, synaptic plasticity and repetitive activation of nociceptors induce central sensitization, leading to the altered gene expression in nociceptors to induce the persistent pain status.[26] In a functional MRI study of IC/BPS patients, changes in brain activity as evidenced by an increment of gray matter volume have been detected in several brain regions.[27] Taken together, these findings suggest that the alterations in the peripheral and central nervous systems are involved in the pathophysiological basis of IC/BPS symptoms although further studies need to identify the true contribution of each of the proposed etiologies to IC/BPS pathogenesis. In addition, because some previous clinical studies examining the pathogenesis of the disease or the efficacy of treatments, which are discussed in the following sections, utilized different patient selection criteria including the old definition of IC developed by NIDDK,[6] it is important to know which patient population was included in each study to understand the implications of trial results for each therapy, and the applicability of the previous results to newly defined IC/BPS [4] needs to be confirmed in future studies.

2. Medical need

In 2011, the AUA guideline reported the algorithm of diagnosis and management for IC/BPS.[4] Recommended treatments for IC/BPS are still limited to conservative therapies, including behavioral therapy, oral or intravesical medication, and bladder hydrodistention. Unfortunately, these treatments often fail with limited efficacy or a short duration of symptom improvement. Other treatments such as botulinum toxin and cyclosporine are optional because of a lack of long-term efficacy or a small number of patients who




Figure 1. Proposed urothelial and neurogenic pathogenesis of interstitial cystitis/bladder pain syndrome. Reproduced with permission from [28].

participated in clinical trials.[4] At present, established IC/BPS treatments with long-term efficacy do not exist.

3. Existing treatments for IC/BPS

For the treatment of IC/BPS, conservative therapies are initially tried and then, if the symptoms are not relieved, less conservative and/or surgical therapies are additionally performed. According to the AUA guidelines for IC/BPS, [4] the recommended treatment options are described in sequence as follows (Table 1): (1) behavioral modification with patient education, (2) physical therapies, oral agents and/or intravesical medications, (3) bladder hydrodistention including transurethral resection/fulguration of Hunner’s lesions, if they exist, (4) neuromodulation, (5) oral administration of cyclosporine A (CyA) or intradetrusor injection of onabotulinum toxin A (BTX-A), and (6) surgical treatment (urinary diversion with or without cystectomy). Among them, efficacy of neuromodulation, CyA and BTX treatments are not validated because of the lack of evidence, and the US Food and Drug Administration does not approve these therapies for the treatment of IC/BPS.

3.1. Behavioral therapy

Patient education regarding fluid intake, avoidance of foods that irritate the bladder, sexual intercourse and clothes improves IC/BPS symptoms. A multicenter placebo-controlled clinical trial of amitriptyline shows that education and behavioral modifications improve the global response assessment (GRA) in 45% of IC/BPS patients in the placebo arm who

Table 1. Existing treatments for IC/BPS.

Compound/treatment	Company	Evidence level
Pentosan polysulfate (oral)	Ortho-NcNeal	1a
Amitriptyline (oral)	Multiple companies	1b
Cyclosporin A (oral)	Multiple companies	1b
DMSO (intravesical)	Multiple companies	1b
Hydroxyzine (oral)	Multiple companies	1b
Intradetrusor BTX-A +hydrodistention	Allergan	1b
Chondroitin sulfate	Multiple companies	2b
Hyaluronic acid (intravesical)	Multiple companies	2b
Patient education/behavioral modification	n/a	3
Organ removal	n/a	3
Sacral neuromodulation	Medtronic	3
Transurethral resection	n/a	3

Evidence levels: 1a, Evidence obtained from meta-analysis of randomized trials; 1b, Evidence obtained from at least one randomized trial; 2a, Evidence obtained from one well-designed controlled study without randomization; 2b, Evidence obtained from at least one other type of well-designed quasi-experimental study; 3, Evidence obtained from well-designed nonexperimental studies, such as comparative studies, correlation studies and case reports; 4, Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities.

were not administered amitriptyline, although there was no control group without behavioral therapy.[29] The intervention is inexpensive and free of risk and should be incorporated into the treatment plans of all patients with IC/BPS.[4]

3.2. Amitriptyline

Amitriptyline is one of the tricyclic antidepressants that has many pharmacological effects such as anticholinergic, antihistamine and narcotic actions.[30,31] Oral administration of amitriptyline significantly improved symptoms, such as pain and urgency (greater than 30% decrease), in 42% of IC/BPS patients compared to 12.5% of the placebo group at 4 months.[30] Adverse events such as drowsiness and nausea are often severe enough to cause some patients to discontinue medication. Foster et al. also reported the efficacy of oral administration of amitriptyline or placebo in IC/BPS patients who received education and behavioral modification.[29] In this study, a GRA rate is moderately or markedly improved in 55% of patients after administration of amitriptyline although amitriptyline in combination with behavioral therapy is not significantly more effective when compared to the behavioral therapy alone group.[29] However, in patients who were able to increase the dose over 50 mg/day, higher improvement was confirmed.[29] At present, amitriptyline is considered the optional treatment for IC/BPS.[4,9]

3.3. Pentosan polysulfate sodium

Pentosan polysulfate sodium (PPS) is a heparin-like agent, which is analogous to glycosaminoglycans (GAG). The urothelium is insulated by surface mucin, which is made up of sulfonated GAG and glycoproteins. Lilly et al. reported that a loss of protective GAG layer lining in the bladder urothelium is responsible, at least in part, for the permeability changes of the IC/BPS bladder.[16] There have been some clinical trials that investigated the efficacy of the PPS for IC/BPS; however, their outcomes are not consistent. For example, it has been revealed that PPS initially improves the O'Leary-Sant Interstitial Cystitis Symptom/Problem Index in 50% of IC/BPS patients although it may take more than 6 months to confirm the efficacy.[32,33] A recent clinical trial (NCT00086684) was terminated because it could not demonstrate the efficacy (www.clinicaltrials.gov). Currently, the efficacy of combined treatment of PPS and bladder hydrodistention is now recruiting participants in a phase IV clinical trial (NCT01895153). Overall at present, PPS is considered as an optional treatment in the AUA guideline due to the lack of evidence, although PPS is an FDA-approved oral agent for IC/BPS.[4]

3.4. Intravesical treatments (DMSO, heparin and lidocaine)

Intravesical treatments with dimethyl sulfoxide (DMSO), heparin or lidocaine have been used as a popular therapeutic

option for IC/BPS.[34] DMSO is the only FDA-approved drug for intravesical treatments. Perez-Marrero et al. reported that 53% of IC/BPS patients exhibited markedly improved symptoms after intravesical administration of 50% DMSO solution, compared to the placebo (18%).[35] The other trials compared the efficacy of DMSO and bacillus Calmette-Guerin (BCG). DMSO significantly reduces pain and urinary frequency in IC/BPS patients with Hunner's lesion, while it does not increase bladder capacity.[36] DMSO is more effective than BCG according to the change in the GRA; however, changes in the health-related quality of life were not observed between DMSO and BCG.[37] Recent studies also showed the efficacy of combined intravesical treatments of DMSO with other drugs such as heparin, hydrocortisone and lidocaine.[38,39]

Three clinical studies for intravesical injection of heparin reported the outcome of IC/BPS symptoms. Heparin administration (30,000 IU) improved symptoms in 56% of patients.[40] Heparin is also more effective when combined with other drugs such as lidocaine and bicarbonate. A clinical trial showed the efficacy of heparin in combination with alkalized lidocaine.[41] In 18 patients, there was a significant reduction in pain, the GRA and urinary urgency after treatments.[41] The AUA guideline indicated heparin as an optional treatment due to the paucity of placebo-controlled clinical trials.

Intravesical lidocaine has also been shown to be an effective treatment for IC/BPS. A clinical trial reported that alkalized lidocaine and sodium bicarbonate relieve IC/BPS symptoms, as reported in the significant decrease of the GRA score, compared to the placebo (30 and 9.6%, respectively).[42] Dysuria, urethral irritation and bladder pain are the adverse events after injection. The success rate is relatively higher than other intravesical drugs, but the post-therapeutic observation period is short; therefore, the treatment is also defined as an option in the AUA guideline.[4]

3.5. Onabotulinum toxin A injection

BTX-A inhibits acetylcholine release from presynaptic cholinergic terminals, suggesting that BTX-A injection into the bladder wall could reduce the urinary symptoms of IC/BPS. Smith et al. reported the treatment efficacy of intradetrusor injection of BTX-A on IC/BPS symptoms in a pilot study.[43] The mean scores of Interstitial Cystitis Symptom Index and Interstitial Cystitis Problem Index were improved by about 70% after 100 – 200 IU BTX-A treatment. However, the effectiveness is short and diminished in 1 year.[43] A randomized clinical trial investigated the efficacy of combination of BTX-A administration with hydrodistention.[44] BTX-A combined with bladder hydrodistention improved the GRA in 70 – 80% of patients compared to 48% of patients with hydrodistention alone. However, the effectiveness was short lasting so that the improvement was seen only in 17 – 21% of patients at 1 year. Several reports

show that repeat BTX-A injections elongate the duration of activity of BTX-A.[45] Half the patients receiving 200 IU experienced dysuria, and some required intermittent self-catheterization although other adverse events were not observed. More recently, Pinto et al. showed that the injection of 100 IU BTX-A is effective to reduce symptoms such as pain intensity, frequency, nocturia in IC/BPS patients with or without Hunner's lesion, although there was no placebo group included.[46] Currently a study of intradetrusor botulinum toxin (phase II) is now recruiting participants in Taiwan (NCT01969773). At present, BTX-A injection is considered to be an optional treatment that can be performed when other treatments fail to relieve the symptoms.[4] Further large-scale, placebo-controlled studies are necessary to confirm the efficacy of BTX-A for the treatment of IC/BPS.

3.6. Cyclosporine A

A randomized clinical trial in IC/BPS patients treated with either CyA or PPS showed the advantage of CyA over PPS after 6 months treatment, and 75% of patients were satisfied with CyA medication with 50% decrease in urinary frequency.[47] Also, in pilot single-arm, non-randomized studies, 91% of IC/BPS patients experienced pain relief after 6 weeks and 87% of patients showed pain reduction and decrement of urinary frequency at 1 year.[48,49] A previous retrospective study also showed that CyA medication is more effective for improving the GRA or the Interstitial Cystitis Symptom Index score in IC/BPS patients with Hunner's lesion compared to those without.[50] Half of the patients presented with adverse events including increased serum creatinine level, hypertension and alopecia. At present, CyA treatment can be considered as an optional treatment, and a phase II clinical trial is recruiting IC/BPS patients (NCT01990898).

3.7. Bladder hydrodistention

If oral and intravesical treatments have failed to relieve the symptoms, cystoscopy, including bladder hydrodistention, under anesthesia would be a next-step treatment. Three observational studies showed that bladder hydrodistention relieves urinary tract symptoms for up to a few months (18 – 56%); however, it does not last for a long duration of time:[51,52] therefore, the treatment is considered as an optional treatment. At present, the efficacy of bladder hydrodistention treatment with warm water (up to 45°C) is being investigated with recruiting participants in Israel (NCT01838486). In addition, there is the possibility of confounding of the results of intravesical treatments for IC/BPS by hydrodistention that takes place during intravesical therapies described above (Section 3.4) because hydrodistention alone may have a therapeutic effect on IC/BPS. Furthermore, because the levels of growth factors and cytokine/chemokine in the bladder could be affected by

hydrodistention, one should be careful interpreting results of gene expression analysis studies of IC/BPS bladder specimens. If Hunner's lesions are found during cystoscopy, fulguration or laser ablation could be performed.

4. Market review

In 1975, Oravisto et al. showed the prevalence of IC/BPS in Finland. The overall prevalence was 10.6 cases per 100,000 and 1.2 female cases per 100,000 women annually diagnosed as IC/BPS.[53] In the Netherlands, the prevalence of IC/BPS was calculated to be 8 to 16 per 100,000 females.[54] Clemens et al. also showed that the prevalence of IC/BPS was 197 female and 41 male cases per 100,000 population.[55] More recently, Berry et al. investigated the prevalence estimation of IC/BPS symptoms in the US, showing that 6.53% of women have the symptoms suggestive of IC/BPS based on telephone interview of 12,752 women.[56] In other words, it is projected that 3,300,000 to 7,900,000 women over 18 years old in the US may have IC/BPS.[56] Overall, it is speculated that IC/BPS may be a common disease, and many IC/BPS patients are underdiagnosed.



Anger et al. published a paper that described the therapies for IC/BPS and their related expenditures using a national database in the US.[57] In 89 patients with IC/BPS, all patients took medication orally, 26% of them received intravesical administration and 22% received hydrodistention.[57] The cost for all treatments is calculated to be \$2208 per patient, not including the clinical testing such as laboratory or radiology examination.[57] The majority of expenditures were spent on oral medical therapies. Thus, despite the high expense, the management of IC/BPS has not been achieved due to the lack of optimal treatment modalities.

5. Current research goals

As discussed above, the existing treatments often fail to improve the symptoms of IC/BPS because of unknown etiologies. Thus, we need to re-evaluate the etiology of IC/BPS, and seek new treatments based on the more detailed mechanisms of IC/BPS, including urothelial dysfunction, neural changes, neurotrophic factors, immune responses and other components. A summary of current ongoing clinical trials is shown in Table 2. Another concern is that there are no suitable animal models of IC/BPS because of the unknown and complex etiology of this disease condition. At present, various animal models – in which we can examine the consequences of each of the pathophysiologic conditions proposed for IC/BPS including increased urothelial permeability or bladder inflammation as well as the pathophysiology of IC/BPS-like symptoms – are being used for the basic research of IC/BPS. However, confirmation of the findings in animal models through clinical studies may validate new targets or modalities for the treatment of IC/BPS.

AQ13

Table 2. Competitive environment table: current clinical trials and basic research.

Compound	Company	Structure	Indication	Current status	Mechanism of action
Pentosan polysulfate	Johnson & Johnson	Xylan, hydrogen sulfate, sodium salt [CAS]	IC/BPS	Phase IV, terminated	Protective effect on GAG layer
Adalimumab	Pfizer	Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer	Rheumatoid arthritis, Crohn's disease, ulcerative colites Off label	Phase III, not recruiting	TNF alpha antagonist
Calcium channel ligand (PD 0299685)	Pfizer	-	Off label	Phase II, completed	Modulating afferent nerves
Sodium chondroitin sulfate	Watson Pharmaceuticals	-	IC/PBS	Phase II, completed	Protective effect on GAG layer
Omalizumab	Roche/ Genentech and Novartis	Immunoglobulin G, anti-(human immunoglobulin E Fc region) (human-mouse monoclonal E25 clone pSVIE26 gamma-chain), disulfide with human-mouse monoclonal E25 clone pSVIE26 kappa-chain, dimer	Asthma, chronic spontaneous urticaria	Phase III, completed	IgG antibody blocks IgE
MN-001	MediciNova		Asthma	Phase II, completed	Blockade of leukotriene
Lidocaine	Biomedical, Inc.	-	Local anesthesia	Phase II, completed	Blockade of peripheral pain
BTX-A+TC-3gel	TheraCoat Ltd	-	Off label	Phase II	Local effect of BTX-A sustained release
AQX-1125	Aquinox Pharmaceuticals, Inc	-	Off label	Phase II	Activate SH2-containing inositol-phosphatase
AF-219	Afferent Pharmaceuticals, Inc.		Off label	Phase II	P2X3 antagonist
Opioid	Multiple	-	Analgesics	Va	Act on opioid receptor
Adenosine antagonist	Multiple	-	Off label	Va	Act on adenosine receptor
Gene therapy	Diamyd Inc	-	Off label	Vb	Targeting afferent nerve

Va: *in vivo* animal study; Vb: *in vitro* animal study.

6. Scientific rationale

6.1. Neural changes inducing afferent hyperexcitability

The pathophysiology of pain and lower urinary tract symptoms associated with IC/BPS is elusive; however, a neurogenic aspect of IC/BPS pathogenesis is hypothesized as follows. Urothelial injury from unknown causes induces the release of substances such as ATP and NO from bladder urothelial cells. Then, immunological responses including mast cell activation alter the condition of the bladder, which introduces production of cytokines and chemokines. These substances stimulate bladder afferent pathways and change their sensitivity and firing properties, resulting in hyperexcitability of afferent pathways, which then provokes a painful condition in IC/BPS patients. (Figure 1).[15] Bladder pain is one of the common findings in IC/BPS. It is speculated that altered bladder conditions including tissue inflammation and bladder afferent hyperexcitability are involved in pain symptoms associated with IC/BPS.[3] Some clinical studies report the evidence showing increased activity of bladder afferent pathways in IC/BPS. For example, a histological analysis reported the inflammatory changes in the bladder obtained from IC/BPS patients, showing that the edematous, rich in

vasodilatation and afferent nerves and mast cells are observed,[58] although inflammatory changes of the bladder are significantly greater in IC/BPS with Hunner's lesion compared to non-Hunner-type IC/BPS, in which inflammatory cell infiltrates are reportedly not found in the bladder tissue.[59,60] Furthermore, the expression of substance P (SP), a neurotransmitter primarily affecting nociceptive C-fiber afferents, is significantly increased in bladder afferent fibers, and increased mRNA levels of SP receptors are also observed in bladder specimens from IC/BPS patients.[61] Capsaicin and resiniferatoxin, potent agonists for TRPV1 channels, desensitize bladder C-fiber afferents at high doses to relieve the painful symptoms in IC/BPS patients,[62,63] although a prospective study could not confirm the efficacy of resiniferatoxin in patients with IC/BPS.[64] Nickel et al. reported the beneficial effect of alkalinized lidocaine, a local anesthetic, on irritable symptoms of IC/BPS in a placebo-controlled, randomized clinical trial.[42] Taken together, these studies may indicate that increased excitability of bladder afferents play a role, at least in part, in the pathophysiology of IC/BPS (Figure 2) although this remains to be proven, other potential pathophysiological factors could also contribute to IC/BPS pathogenesis (see Section 1.2).




Figure 2. Proposed summary of the events involved in chronic inflammation of the bladder and hyperexcitability of C-fiber bladder afferent pathways. The events that occur following chronic bladder inflammation (1) are indicated in sequential numbers (2–5). Potential therapeutic modalities targeting enhanced synaptic transmission at the spinal cord level or inflammatory changes in the bladder, which were discussed in the text, are also shown in the boxes. DRG, dorsal root ganglia. Reproduced with permission from [28].

6.2. Nerve growth factor

Neurotrophic factors such as nerve growth factor (NGF) are observed in various inflammatory cells, such as lymphocytes and mast cells. It has been shown that NGF is involved in inflammation, an allergic reaction, and altered neurological conditions in IC/BPS.[65,66] An immunohistological study reports that expression of NGF is increased in the bladder of IC/BPS patients.[67] Neurotrophic factors including NGF are also found in urine obtained from IC/BPS patients,[68,69] and a recent meta-analysis study reported that urinary NGF could be a useful biomarker for the differential diagnosis of IC/BPS and overactive bladder as well as a predictive biomarker to help guide treatments.[69] In experimental rat studies, intravesical or intrathecal application of exogenous NGF elicits nociceptive effects and micturition frequency.[70–72] These data suggest that NGF is increased in the pathological condition and provokes bladder pain in IC/BPS.[73] Therefore, inhibition of NGF may be a therapeutic potential for lower urinary tract symptoms in IC/BPS patients (Figure 2). Evans et al. reported the clinical outcome of tanezumab, monoclonal NGF neutralizing antibody for IC/BPS in phase II study.[74] Tanezumab was administered intravenously in 68 patients with IC/BPS, and effective for self-reported pain and urinary urgency for 6 weeks compared to the placebo group, while voiding frequency and voided volume are not affected.[74] In this study, abnormal peripheral sensation is the most common adverse event, and vertigo and headache present as other adverse events. Furthermore, serious adverse events were reported by another clinical trial of tanezumab for osteoarthritis, in which bone necrosis developed and total joint replacements were needed, and several clinical trials have since been terminated (www.clinicaltrials.gov) despite that proof-of-concept evidence has been provided for effectiveness of intervention of the NGF system for the treatment of IC/BPS.[74] To avoid systemic adverse events of anti-NGF therapy, intravesical treatments may be a reasonable approach. In this regard, we recently reported that intravesical administration of liposome-NGF antisense conjugates suppresses NGF expression in the bladder mucosa and bladder overactivity in rats with acetic acid-induced cystitis.[75] Therefore, local suppression of NGF in the bladder using intravesical liposome-based delivery techniques could be an attractive approach for IC/BPS treatment, which can avoid systemic side effects although further studies are needed to clarify this point.

6.3. Cytokine and chemokine expression and IC/BPS

Inflammatory cytokines/chemokines have also been considered as potent pathophysiological factors involved in IC/BPS.[76–78] Previous studies revealed that cytokines/chemokines such as interleukin-2 (IL-2), IL-6 and IL-8 were significantly increased in urine from patients with IC/BPS compared to controls.[76,77] In contrast, the serum level of IL-4, which suppresses the secretion of inflammatory cytokines like IL-1 β , TNF α and

IL-6,[79–81] is decreased in IC/BPS patients and normalized by the oral treatment with suplatast tosilate.[79] Also, in IC/BPS patients with Hunner's lesion, IL-6, 10 and 17A as well as iNOS expression and the number of mast cells were significantly increased in the bladder mucosa, which was biopsied before hydrodistention compared to healthy controls.[82]

Several chemokines also act on many functions such as the recruitment of leukocytes, tumor growth, angiogenesis and organ sclerosis.[83] CXCR3 and its associated ligands, interferon- γ (INF- γ)-inducible chemokines (CXCL9, CXCL10 and CXCL11), are involved in autoimmune diseases. CXCR3 is expressed in various cells including helper T cells, epithelial cells and vascular pericytes.[84,85] Activation of INF- γ induces the secretion of CXCL10 from endocrine epithelial cells, and then CXCL10 recruits helper T cells expressing CXCR3 to produce INF- γ . This vicious circle may be involved in endocrine autoimmune diseases.[83] Sakthivel et al. report the increment of serum levels of CXCR3 associated ligands in IC/BPS patients.[86] They also report that the similar mRNA changes of CXCL10 and CXCL11 are observed in cyclophosphamide (CYP)-induced cystitis mice, and the altered expression is blocked by anti-CXCL10 antibodies.[86] We also investigated gene expression in bladder samples obtained from IC/BPS patients with Hunner's lesion before hydrodistention using DNA microarray. We found that the upregulation of CXCR3 associated chemokines as well as TNFSF14 in the bladder urothelium,[87] which exacerbates the inflammatory conditions, may inhibit urothelial reproduction in the Hunner's lesion of the bladder.[87] It has also been investigated that altered expression of cytokines and chemokines by multiple antigen bead assay using biopsied bladder tissues obtained after hydrodistention, showing that several cytokines such as IL-16, VCAM-1 and ICAM are increased.[88] Multivariate analysis shows that VCAM-1 and ICAM-1 are useful for distinguishing bladder tissue and urine of IC/BPS patients from those of control patients.[88] The blockade of cytokine/chemokine production in relation to IC/BPS seems beneficial for treatments of IC/BPS; however, the efficacy was not confirmed by the clinical study. Bosch et al. investigated the efficacy of adalimumab, a biological agent that blocks TNF- α , on the lower urinary tract symptoms in IC/BPS patients (phase III study: NCT01295814). Adalimumab treatment significantly improved the painful symptoms, urinary urgency and frequency symptoms at 12 weeks compared to the baseline.[89] However, statistically significant improvements could not be obtained in any outcome measures from patients with adalimumab compared to control patients.[89] Thus, at present, systemic blockade of TNF- α fails to demonstrate the treatment efficacy for IC/BPS; however, in an animal study, the local blockade of TNF- α by using herpes simplex virus (HSV) vectors expressing soluble TNF- α receptor can reduce bladder pain behavior and bladder overactivity induced by bladder irritation.[90] Further investigations are needed to elucidate the possibility of clinical translation of the HSV-based cytokine/chemokine blockade treatment for IC/BPS.

6.4 Calcium channel ligand

The $\alpha 2\delta$ subunit of ligand-gated calcium ion channels mediates activation of nociceptive afferents and is implicated in chronic pain; therefore, gabapentin and pregabalin that can block the calcium ion channel $\alpha 2\delta$ subunit have been indicated for the treatment of neuropathic pain.[91] There are some clinical studies suggesting that gabapentin may have efficacy in the refractory genitourinary pain of IC/BPS although they are open-label, uncontrolled studies with a limited number of patients.[92,93] Nickel et al. investigated the effect of PD-0299685, a calcium channel $\alpha 2\delta$ ligand, in IC/BPS patients.[94] PD-0299685 significantly reduces painful symptoms after 12 weeks compared to control patients; however, the trial could not get the proof-of-concept demonstration due to a lack of significant improvements in Interstitial Cystitis Symptom Index score.[94]

6.5. Sodium chondroitin sulfate and liposomes

Chondroitin sulfate is one important component of mucinous GAG layer in the urothelium, which may be altered in IC/BPS. Nickel et al. showed the efficacy of intravesical sodium chondroitin sulfate for symptoms of IC/BPS.[95] In this randomized controlled trial, although 38% of patients treated with chondroitin sulfate showed moderate or marked improvement, the treatment has minor benefit and its use as a monotherapy is not indicated for this condition.[95] At present, a clinical trial is recruiting participants to investigate the efficacy of a combined intravesical therapy of hyaluronic acid/chondroitin sulfate with transurethral resection of Hunner's lesion (NCT01813565: phase II).

Liposomes are the earliest prototype of nanoparticles (particles with one of the dimensions in nanometers), which consist of soluble substances enclosed by concentric bilayers.[96,97] Chuang et al. reported clinical outcomes of intravesical application of liposomes in IC/BPS patients compared to oral PPS.[98] In this open-label, unblinded prospective study of 24 IC/BPS patients, the comparable efficacy of liposomes to oral PPS was demonstrated by significant decrease in pain and urinary urgency symptoms in the liposome treatment arm. No serious adverse events and no significant worsening of symptoms were observed during follow-ups. Thus, liposome is one candidate for the treatment of IC/BPS; however, prospective trials with a large number of patients are needed to establish the efficacy of this treatment. In addition, because there is a possibility that hydrodistention of the bladder may confound the results of intravesical liposomal studies, care should be taken to avoid bladder overdistention during intravesical treatments including liposomal therapy.

7. Competitive environment

Many research and clinical studies, which evaluated various drugs for treatment of IC/PBS, were terminated due to the

lack of efficacy or adverse events. Described below are other ongoing trials of drug treatments.

7.1. AF-219 (P2X3 receptor antagonist)

Urothelial cells modulate afferent signals from chemical and mechanical stimuli in the bladder, and then the signals are sent to the CNS (Figure 1).[3] Bladder distention releases ATP from the urothelium, and ATP activates P2X3 receptors in bladder afferents to modulate bladder activity evidenced by experimental studies of P2X3 knockout mice.[99,100] There is also evidence showing that the stimulatory ATP mechanism is upregulated in the bladder from IC/BPS patients because ATP release from urothelial cells in addition to urothelial expression of P2X3 ATP receptors is increased in IC/BPS patients.[101–104] It has also been reported that urothelially released ATP is enhanced in cats with feline-type IC.[105] Based on these results, a P2X3 receptor antagonist (AF-219) has been tested for IC/BPS patients in a placebo-controlled, randomized phase II study (NCT01569438) (Table 2).

7.2. Intranasal oxytocin

A previous report has shown that IC/BPS patients have reduced bladder pain during breastfeeding.[106] There is a speculation that the hormones related to the postpartum lactation relieve the symptoms of IC/BPS, because postpartum lactation decreases levels of stress, which exacerbates IC-related pain. Black et al. reported that oxytocin attenuates the stress condition induced by bladder distention in rats.[107] A prospective clinical trial of intranasal oxytocin versus intranasal saline for bladder pain of IC/BPS is now recruiting participants (NCT00919802).

7.3. Drug delivery systems

Systemic administration including oral intake often fails to treat IC/BPS. Topical application of drugs, such as lidocaine, shows efficacy with lower adverse events; however, problems such as the short duration of effectiveness remain. LiRIS® is a solid mini pellet, which encases lidocaine in a water-permeable flexible tube and releases lidocaine continuously.[108] The phase II randomized clinical trial is now recruiting participants for evaluating the efficacy of LiRIS® in female patients with IC/BPS (NCT01824303) (Table 2). For sustained release of drugs, intravesical application of TC-3 gel with BTX-A is also currently being investigated (NCT01997983) (Table 2). Liquid TC-3 gel containing BTX-A is transformed into a solid state in the bladder, and the TC-3 gel dissolves in the urine to release the BTX-A. The mechanism makes it possible for the sustained release of BTX-A.

7.4. AQX-1125

AQX-1125 activates SH2-containing inositol-5'-phosphatase (SHIP1), which modulates the PI3K pathway.[109] Activation of the PI3K pathway is involved in immune cell

signaling inducing chronic inflammation. SHIP1 is predominantly expressed in immune cells derived from bone marrow tissues. It is considered that activation of SHIP1 has an anti-inflammatory effect by negatively regulating the PI3K pathway to reduce the immunological reaction.[109] Oral AQX-1125 inhibited the nociceptive pain scores in the rat model of CYP-induced cystitis; therefore, AQX-1125 is one of the candidate drugs to be studied in the phase II clinical trial (NCT01882543) (Table 2).

7.5. MN-001 (tipelukast)

MN-001 (tipelukast) is an orally bioavailable small molecule compound, which exerts its effects to produce anti-fibrotic and anti-inflammatory activity, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDEs) and inhibition of 5-lipoxygenase.[110] This compound has been tested for IC/BPS patients in the randomized phase II clinical trial (NCT00295854) (Table 2).

8. Potential development issues

Based on basic research findings, there are several suggestive mechanisms by which the painful and irritable symptoms are induced in IC/BPS patients. Among them, urothelial dysfunction with increased permeability and urothelially released substances, and sensitization of bladder afferent pathways including C-fiber afferents could contribute to the development of IC/BPS symptoms.[111] Therefore, therapies targeting the sensory activity at both peripheral and central levels may be effective for reducing symptoms of IC/BPS patients.

8.1. Opioids

Persistent bladder pain is often resistant to nonsteroidal anti-inflammatory drugs and needs more effective drugs such as morphine or oxycodone. However, these opioid treatments have potential risks such as tolerance and dependency. Therefore, the aforementioned EAU guideline of CPPS has shown that the indication of opioids is limited to selected patients. To avoid the side effects, the endogenous opioid could be one of the candidates for the treatment of bladder pain. Enkephalins, one of the endogenous opioids, are expressed in sensory and motor neurons and increased by nerve injury.[112] Supraspinal application of enkephalin inhibits the micturition reflex in rats, suggesting that upregulation of enkephalin levels in the brain and/or the spinal cord has inhibitory effects on the micturition reflex.[113] Yokoyama et al. showed that intradetrusor injection of HSV vectors encoding preproenkephalin, the precursor of enkephalins, suppresses bladder overactivity and nociceptive behavior induced by intravesical application of capsaicin, whereas the effects of vector-mediated enkephalin delivery are not observed in normal rats.[114,115] suggesting that HSV vector-

mediated delivery of enkephalin has therapeutic effects on bladder nociceptive responses without affecting normal micturition. Thus, the increased levels of endogenous opioids such as enkephalin seem to be an effective modality for the treatment of IC/BPS symptoms. In humans, the efficacy of herpes virus vector NP2 encoding enkephalin on intractable cancer pain has been evaluated by the phase II clinical trial (NCT01291901).

8.2. Adenosine receptors

Adenosine is expressed in various organs including nervous systems, and acts as a neuromodulator to exert physiological effects in various organs. A number of studies have shown that activation of A1 receptors produces antinociception in several pain models, and A2A receptor knockout attenuates nociceptive responses in mouse models of somatic pain.[116–118] A recent study has also shown that systemic or intrathecal application of ZM24138 (A2A receptor antagonist) significantly reduces micturition intervals in rats with acetic acid-induced cystitis compared to control.[111] These results indicate that the blockade of A2A receptor in the spinal cord might suppress peripheral pain. In the clinical setting, adenosine is thought to be useful in the treatment of allodynia, and the efficacy of an adenosine A2A receptor antagonist for neuropathic pain was investigated in the clinical trial (NCT00349921) although the trial has been terminated because of the small number of participants and lack of data. However, at least, they reported no serious events in the trial, suggesting that adenosine receptor-targeting treatments are safe in humans. Further investigation is needed to evaluate the efficacy of this class of compounds for IC/BPS.

8.3. Glycine receptor

Glycine is one of the inhibitory amino acids, which plays a role as a neurotransmitter in the spinal cord and preganglionic neurons. Glycine also exerts inhibitory effects on bladder contractions and urethral sphincter activity and might be involved in the pathological bladder conditions associated with spinal cord injury or bladder outlet obstruction.[119–121] The extracellular level of glycine is regulated by two subtypes of the glycine transporter (GlyT), GlyT1 and GlyT2.[122] Previous studies have shown an efficacy of GlyT inhibitors for chronic pain [123,124] and bladder overactivity in rats.[125] Intrathecal application of GlyT2 inhibitor suppresses bladder overactivity induced by CYP and pain behavior induced by resiniferatoxin in rats.[125] These data suggest that inhibition of GlyT2 in the spinal cord might have a therapeutic potential for IC/BPS. Recently, VVZ-149, an inhibitor of GlyT2 and serotonin receptors, has been developed as a new analgesic agent, and the safety, tolerability and pharmacokinetics of the agent were investigated in the phase I clinical trial (NCT01905410).

8.4 Gene therapy for modulating the cytokine level

TNF- α is involved in various functions that contribute to tissue inflammation and tumor progression. For example, TNF- α induces adhesion molecules and other cytokines such as IL-1 and IL-6, and stimulates inflammatory cells. [126] It has also been recognized that TNF- α is involved in neuropathic pain [127] and acts on the peripheral tissue and the spinal cord. [127,128] The neutralization of TNF- α activity by the antibody or TNF- α soluble receptors (TNF- α sR) attenuates the pain sensation in several rat pain models. [128–130] Recently, it has been reported that gene therapy of TNF- α sR using replication-deficient HSV vectors reduces TNF- α protein levels of the bladder, leading to the suppression of cytokines such as IL-1 and IL-6 to relieve bladder pain and urinary frequency in a rat cystitis model. [90] The TNF- α sR-expressing vector treatment also suppresses the bladder overactivity induced by intravesical application of resiniferatoxin in association with the reduction in myeloperoxidase activity in the bladder. [90] Based on the results of HSV preclinical studies, a phase I trial using HSV-enkephalin gene therapy to treat chronic pain due to cancer has been completed in 10 patients with remarkable pain-relieving activity without any HSV vector-related toxicity. [131] Thus, there is the possibility that HSV vector-based gene therapy could be effective for the treatment of IC/BPS symptoms although the long-term safety of HSV vector-based gene therapy needs confirming in larger-population clinical studies.

8.5. PDE inhibitor

Cyclic nucleotide PDE is an enzyme that metabolizes the intracellular signal transmitters cyclic adenosine and guanosine monophosphate (cAMP and cGMP) into 5'-adenosine monophosphate (5'-AMP) and 5'-guanosine monophosphate (5'-GMP), respectively, and plays an important role in the regulation of intracellular cAMP and cGMP concentrations. PDE inhibitors can relax bladder smooth muscle and improve vascular endothelial function. [132,133] Tadalafil, a long-acting PDE5 inhibitor, is used for erectile dysfunction and lower urinary tract symptoms associated with benign prostate hyperplasia. [134] In an animal study, PDE4 inhibitor, which is expressed in inflammatory cells such as leukocytes, is effective in reducing bladder irritation induced by HCl. [135] Chen et al. also reported that the low dose of sildenafil, a PDE5 inhibitor, was effective in the treatment for IC/BPS because symptoms and bladder capacity were significantly improved after the treatment. [136]

9. Conclusion

As discussed in this review, various etiologies of IC/BPS have been postulated, which include urothelial dysfunction with increased permeability, alterations in growth factor expression, neurogenic inflammation with mast cell activation and

increased NO levels, autoimmune reaction, infection, increased afferent activity and changes in CNS responses. However, there is not a pathological process that is applicable to every patient with IC/BPS. Thus, it is presumed that IC/BPS can be induced by multiple pathophysiological factors, which interact with each other, thereby leading to similar clinical manifestations. Unfortunately, at present, there is no optimal treatment for IC/BPS, but newer drugs and treatment modalities are currently under investigation in various clinical trials. Among them, several interventions, including sustained release and retaining techniques and drugs that act on afferent neural pathways, are emerging and may be promising. In addition, although sensitization of the CNS has been proposed to be involved in the pathogenesis of IC/BPS (see Section 1.2), the effort for developing new therapies targeting the brain or the spinal cord is still limited.

10. Expert opinion

Although the etiology of BPS/IC is not known, it is considered that the epithelial layer damage leads the toxic substances into the deep layer, which induces bladder pain and other symptoms. In addition, it is still not known how the “leaky urothelium” developed in IC/BPS patients. In animal studies, blocking various proposed causes discussed in this review seems to be effective for the treatments of IC/BPS; however, the results in animal studies have not come to fruition in clinical trials. One of the reasons for the discrepancy could be the subtype of IC/BPS. The European Society for the Study of Interstitial Cystitis (ESSIC) proposed that Hunner’s lesion, which is often called “ulcer,” is not a typical chronic ulcer, but rather a distinctive inflammatory lesion presenting a characteristic deep rupture through the mucosa. Accordingly, it is proposed that patients with Hunner’s lesion are classified into the ESSIC type 3. [137] In a previous study, gene expression analysis in the bladder of IC/BPS patients with Hunner’s lesion shows the overexpression of genes related to immune and inflammatory responses including helper T-cell-related chemokines, whereas similar expression changes are not found in IC/BPS without Hunner’s lesion. [87] Thus, IC/BPS with Hunner’s lesion might be a different entity from that without Hunner’s lesion. [2] In the AUA guidelines, cystoscopy is not recommended as a diagnostic test because typical cystoscopic findings such as glomerulations are often seen not only in IC/BPS but also in other conditions. Therefore, the data from many clinical trials were obtained from the mixture of IC/BPS with and without Hunner’s lesion. This situation might be one of the reasons why many drugs fail to demonstrate overall efficacy. It is possible that the cystoscopic evaluation of the existence of Hunner’s lesion at least in participants of clinical trials increases the chance of successful outcomes. We consider that it is important to draw a distinction between these two conditions because the prevalence of Hunner’s lesion among IC/BPS patients is higher

than previously expected.[2,10] In this regard, cystoscopic evaluation with a narrow band imaging system could increase the rate and accuracy of detection of bladder changes including Hunner's lesion in IC/BPS.[138] In the EAU guideline, the treatment is decided by the presence or absence of Hunner's lesion. Transurethral resection is recommended when Hunner's lesion exists. In addition, Nickel et al. proposed the individualized therapeutic strategies based on the phenotype of IC/BPS symptoms, which is classified by the UPOINT categorization (urinary, psychosocial, organ-specific, infection, neurologic or non-bladder, and tenderness of pelvic floor). [139] Taken together, we presume that standardized classification of IC/BPS is important for not only further investigation of etiology, but also the evaluation of efficacy of new treatments.

Bibliography

1. Hunner G. A rare type of bladder ulcer in women; report of cases. *Boston Med Surg J.* 1915;172:660–664.
2. Fall M, Logadottir Y, Pecker R. Interstitial cystitis is bladder pain syndrome with Hunner's lesion. *Int J Urol.* 2014;21 (Suppl 1):79–82.
- * **The characteristics and current status of Hunner's lesion in IC/BPS are well summarized.**
3. Yoshimura N, Seki S, Chancellor MB, et al. Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. *Urology.* 2002;59(5 Suppl 1):61–67.
4. Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. *J Urol.* 2011;185 (6):2162–2170.
- ** **This AUA guideline describes the definition of IC/BPS and current clinical treatment option, which would be useful for designing the future clinical investigations of IC/BPS.**
5. Homma Y, Ueda T, Ito T, et al. Japanese guideline for diagnosis and treatment of interstitial cystitis. *Int J Urol.* 2009;16 (1):4–16.
- * **The standardized methods for the diagnosis of IC/BPS including cystoscopic evaluation are well described.**
6. Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. *J Urol.* 1988;140(1):203–206.

Declaration of interest

The authors' research has been supported by grants from the National Institutes of Health (DK088836 and P01DK093424) and the Department of Defense (W81XWH-12-1-0565).

N Yoshimura has acted as a consultant for Astellas Pharma Inc. and has received research grants from Astellas Pharma Inc., GlaxoSmithKline and Ono Pharmaceutical. MB Chancellor has acted as a consultant for Allergan, Astellas Pharma, Cook, Medtronic, Pfizer and Targacept. He has provided commercial assistance to Lipella Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed

7. Ibrahim IA, Diokno AC, Killinger KA, et al. Prevalence of self-reported interstitial cystitis (IC) and interstitial-cystitis-like symptoms among adult women in the community. *Int Urol Nephrol.* 2007;39 (2):489–495.
8. Bosch PC, Bosch DC. Treating interstitial cystitis/bladder pain syndrome as a chronic disease. *Rev Urol.* 2014;16(2):83–87.
9. Fall M, Baranowski AP, Elneil S, et al. EAU guidelines on chronic pelvic pain. *Eur Urol.* 2010;57(1):35–48.
- ** **This EAU guideline is useful for defining the treatment strategies for not only IC/BPS, but also CPPS**
10. Logadottir Y, Fall M, Kabjorn-Gustafsson C, et al. Clinical characteristics differ considerably between phenotypes of bladder pain syndrome/interstitial cystitis. *Scand J Urol Nephrol.* 2012;46(5):365–370.
11. Waxman JA, Sulak PJ, Kuehl TJ. Cystoscopic findings consistent with interstitial cystitis in normal women undergoing tubal ligation. *J Urol.* 1998;160(5):1663–1667.
12. Pecker R, Fall M. Treatment guidelines for classic and non-ulcer interstitial cystitis. *Int Urogynecol J Pelvic Floor Dysfunct.* 2000;11(1):23–32.
13. Furuya R, Masumori N, Furuya S, et al. Glomerulation observed during transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is a common finding but no predictor of clinical outcome. *Urology.* 2007;70(5):922–926.
14. Simon LJ, Landis JR, Erickson DR, et al. The Interstitial Cystitis Data Base Study: concepts and preliminary baseline descriptive statistics. *Urology.* 1997;49(5A Suppl):64–75.
15. Chancellor MB, Yoshimura N. Treatment of interstitial cystitis. *Urology.* 2004;63(3 Suppl 1):85–92.
16. Lilly JD, Parsons CL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. *Surg Gynecol Obstet.* 1990;171(6):493–496.
17. Buffington CA, Woodworth BE. Excretion of fluorescein in the urine of women with interstitial cystitis. *J Urol.* 1997;158(3 Pt 1):786–789.
18. Keay S, Warren JW, Zhang CO, et al. Antiproliferative activity is present in bladder but not renal pelvic urine from interstitial cystitis patients. *J Urol.* 1999;162(4):1487–1489.
19. Conrads TP, Tocci GM, Hood BL, et al. CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients. *J Biol Chem.* 2006;281(49):37836–37843.
20. Kim J, Keay SK, Freeman MR. Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation. *BJU Int.* 2009;103 (4):541–546.
21. Slobodov G, Feloney M, Gran C, et al. Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. *J Urol.* 2004;171 (4):1554–1558.

22. Heinrich M, Oberbach A, Schlichting N, et al. Cytokine effects on gap junction communication and connexin expression in human bladder smooth muscle cells and suburothelial myofibroblasts. *PLoS One*. 2011;6(6):e20792.
23. Birder LA, Wolf-Johnston A, Buffington CA, et al. Altered inducible nitric oxide synthase expression and nitric oxide production in the bladder of cats with feline interstitial cystitis. *J Urol*. 2005;173(2):625–629.
24. Lavelle JP, Meyers SA, Ruiz WG, et al. Urothelial pathophysiological changes in feline interstitial cystitis: a human model. *Am J Physiol Renal Physiol*. 2000;278(4):F540–F553.
25. Zeng Y, Wu XX, Homma Y, et al. Uroplakin III-delta4 messenger RNA as a promising marker to identify nonulcerative interstitial cystitis. *J Urol*. 2007;178(4 Pt 1):1322–1327; discussion 27.
26. Denk F, McMahon SB. Chronic pain: emerging evidence for the involvement of epigenetics. *Neuron*. 2012;73(3):435–444.
- * **This review contains the perspective of the pathophysiology of chronic pain, which can be applied to the pathogenesis of IC/BPS symptoms.**
27. Kairys AE, Schmidt-Wilcke T, Puiu T, et al. Increased brain gray matter in the primary somatosensory cortex is associated with increased pain and mood disturbance in patients with interstitial cystitis/painful bladder syndrome. *J Urol*. 2015;193(1):131–137.
28. Yoshimura N, Oguchi T, Yokoyama H, et al. Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis. *Int J Urol*. 2014;21(Suppl 1):18–25.
29. Foster HE Jr, Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome. *J Urol*. 2010;183(5):1853–1858.
30. van Ophoven A, Pokupic S, Heinecke A, et al. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. *J Urol*. 2004;172(2):533–536.
31. Hertle L, van Ophoven A. Long-term results of amitriptyline treatment for interstitial cystitis. *Aktuelle Urol*. 2010;41(Suppl 1):S61–65.
32. Nickel JC, Barkin J, Forrest J, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. *Urology*. 2005;65(4):654–658.
33. Davis EL, El Khoudary SR, Talbott EO, et al. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. *J Urol*. 2008;179(1):177–185.
34. Neuhaus J, Schwalenberg T. Intravesical treatments of bladder pain syndrome/interstitial cystitis. *Nat Rev Urol*. 2012;9(12):707–720.
- * **This is a comprehensive summary of the current status of intravesical treatment of IC/BPS**
35. Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. *J Urol*. 1988;140(1):36–39.
36. Peeker R, Haghsheno MA, Holmang S, et al. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. *J Urol*. 2000;164(6):1912–1915; discussion 15–6.
37. Sairanen J, Leppilahti M, Tammela TL, et al. Evaluation of health-related quality of life in patients with painful bladder syndrome/interstitial cystitis and the impact of four treatments on it. *Scand J Urol Nephrol*. 2009;43(3):212–219.
38. Hung MJ, Chen YT, Shen PS, et al. Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. *Int Urogynecol J*. 2012;23(11):1533–1539.
39. Stav K, Beberashvili I, Lindner A, et al. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. *Urology*. 2012;80(1):61–65.
40. Parsons CL, Housley T, Schmidt JD, et al. Treatment of interstitial cystitis with intravesical heparin. *Br J Urol*. 1994;73(5):504–507.
41. Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. *J Sex Med*. 2012;9(1):207–212.
42. Nickel JC, Moldwin R, Lee S, et al. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. *BJU Int*. 2009;103(7):910–918.
43. Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. *Urology*. 2004;64(5):871–875; discussion 75.
44. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. *BJU Int*. 2009;104(5):657–661.
45. Giannantoni A, Mearini E, Del Zingaro M, et al. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. *Curr Drug Deliv*. 2010;7(1):1–4.
46. Pinto R, Lopes T, Costa D, et al. Ulcerative and nonulcerative forms of bladder pain syndrome/interstitial cystitis do not differ in symptom intensity or response to onabotulinum toxin A. *Urology*. 2014;83(5):1030–1034.
47. Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. *J Urol*. 2005;174(6):2235–2238.
48. Forsell T, Ruutu M, Isoniemi H, et al. Cyclosporine in severe interstitial cystitis. *J Urol*. 1996;155(5):1591–1593.
49. Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. *J Urol*. 2004;171(6 Pt 1):2138–2141.
50. Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. *J Urol*. 2012;188(4):1186–1191.
51. Ottem DP, Teichman JM. What is the value of cystoscopy with hydrodistension for interstitial cystitis? *Urology*. 2005;66(3):494–499.
52. Erickson DR, Kunselman AR, Bentley CM, et al. Changes in urine markers and symptoms after bladder distention for interstitial cystitis. *J Urol*. 2007;177(2):556–560.
53. Oravisto KJ. Epidemiology of interstitial cystitis. *Ann Chir Gynaecol Fenn*. 1975;64(2):75–77.
54. Bade JJ, Rijcken B, Mensink HJ. Interstitial cystitis in The Netherlands: prevalence, diagnostic criteria and

- therapeutic preferences. *J Urol.* 1995;154(6):2035–2037; discussion 37–8.
55. Clemens JQ, Meenan RT, Rosetti MC, et al. Prevalence and incidence of interstitial cystitis in a managed care population. *J Urol.* 2005;173(1):98–102; discussion 02.
 56. Berry SH, Elliott MN, Suttrop M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. *J Urol.* 2011;186(2):540–544.
 57. Anger JT, Zabihi N, Clemens JQ, et al. Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome. *Int Urogynecol J.* 2011;22(4):395–400.
 58. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. *Urology.* 2001;57(6 Suppl 1):47–55.
 59. Erickson DR, Tomaszewski JE, Kunselman AR, et al. Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndrome. *J Urol.* 2008;179(5):1850–1856.
- ** This article described the difference in inflammatory changes of the bladder between IC/BPS with Hunner's lesion and that without**
60. Tyagi P, Killinger K, Tyagi V, et al. Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. *J Urol.* 2012;187(6):2243–2248.
 61. Sukiennik A, Carr DB, Bonney I, et al. The effect of short-term epidural local anesthetic blockade on urinary levels of substance P in interstitial cystitis. *Anesth Analg.* 2004;98(3):846–850, table of contents.
 62. Lazzeri M, Beneforti P, Benaim G, et al. Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. *J Urol.* 1996;156(3):947–952.
 63. Lazzeri M, Beneforti P, Spinelli M, et al. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. *J Urol.* 2000;164(3 Pt 1):676–679.
 64. Payne CK, Mosbaugh PG, Forrest JB, et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. *J Urol.* 2005;173(5):1590–1594.
 65. Levi-Montalcini R, Skaper SD, Dal Toso R, et al. Nerve growth factor: from neurotrophin to neurokin. *Trends Neurosci.* 1996;19(11):514–520.
 66. Freund-Michel V, Frossard N. The nerve growth factor and its receptors in airway inflammatory diseases. *Pharmacol Ther.* 2008;117(1):52–76.
 67. Lowe EM, Anand P, Terenghi G, et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. *Br J Urol.* 1997;79(4):572–577.
 68. Okragly AJ, Niles AL, Saban R, et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. *J Urol.* 1999;161(2):438–441; discussion 41–2.
 69. Qu HC, Zhang W, Yan S, et al. Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis. *PLoS One.* 2014;9(9):e106321.
 70. Dmitrieva N, Shelton D, Rice AS, et al. The role of nerve growth factor in a model of visceral inflammation. *Neuroscience.* 1997;78(2):449–459.
 71. Chuang YC, Fraser MO, Yu Y, et al. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. *J Urol.* 2001;165(3):975–979.
 72. Seki S, Sasaki K, Fraser MO, et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. *J Urol.* 2002;168(5):2269–2274.
 73. Yoshimura N, de Groat WC. Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation. *J Neurosci.* 1999;19(11):4644–4653.
 74. Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. *J Urol.* 2011;185(5):1716–1721.
 75. Kashyap M, Kawamorita N, Tyagi V, et al. Down-regulation of nerve growth factor expression in the bladder by antisense oligonucleotides as new treatment for overactive bladder. *J Urol.* 2013;190(2):757–764.
 76. Erickson DR, Xie SX, Bhavanandan VP, et al. A comparison of multiple urine markers for interstitial cystitis. *J Urol.* 2002;167(6):2461–2469.
 77. Peters KM, Diokno AC, Steinert BW. Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guerin treat interstitial cystitis by altering the immune profile in the bladder? *Urology.* 1999;54(3):450–453.
 78. Keay S. Cell signaling in interstitial cystitis/painful bladder syndrome. *Cell Signal.* 2008;20(12):2174–2179.
 79. Ueda T, Tamaki M, Ogawa O, et al. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T. *J Urol.* 2000;164(6):1917–1920.
 80. te Velde AA, Huijbens RJ, Heije K, et al. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. *Blood.* 1990;76(7):1392–1397.
 81. Gautam S, Tebo JM, Hamilton TA. IL-4 suppresses cytokine gene expression induced by IFN-gamma and/or IL-2 in murine peritoneal macrophages. *J Immunol.* 1992;148(6):1725–1730.
 82. Logadottir Y, Delbro D, Fall M, et al. Cytokine expression in patients with bladder pain syndrome/interstitial cystitis ESSIC type 3C. *J Urol.* 2014;192(5):1564–1568.
 83. Rotondi M, Chiovato L, Romagnani S, et al. Role of chemokines in endocrine autoimmune diseases. *Endocr Rev.* 2007;28(5):492–520.
 84. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. *J Exp Med.* 1998;187(1):129–134.
 85. Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. *J Exp Med.* 1998;187(6):875–883.
 86. Sakthivel SK, Singh UP, Singh S, et al. CXCL10 blockade protects mice from cyclophosphamide-induced cystitis. *J Immune Based Ther Vaccines.* 2008;6(1):6.
 87. Ogawa T, Homma T, Igawa Y, et al. CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. *J Urol.* 2010;183(3):1206–1212.

88. Corcoran AT, Yoshimura N, Tyagi V, et al. Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. *World J Urol.* 2013;31(1):241–246.
89. Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. *J Urol.* 2014;191(1):77–82.
90. Funahashi Y, Oguchi T, Goins WF, et al. Herpes simplex virus vector mediated gene therapy of tumor necrosis factor- α blockade for bladder overactivity and nociception in rats. *J Urol.* 2013;189(1):366–373.
91. Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. *CNS Drugs.* 2008;22(5):417–442.
92. Hansen HC. Interstitial cystitis and the potential role of gabapentin. *South Med J.* 2000;93(2):238–242.
93. Sasaki K, Smith CP, Chuang YC, et al. Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. *Tech Urol.* 2001;7(1):47–49.
94. Nickel JC, Crossland A, Davis E, et al. Investigation of a Ca²⁺ channel α 2 δ ligand for the treatment of interstitial cystitis: results of a randomized, double-blind, placebo controlled phase II trial. *J Urol.* 2012;188(3):817–823.
95. Nickel JC, Hanno P, Kumar K, et al. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. *Urology.* 2012;79(6):1220–1224.
96. Gregoriadis G, Ryman BE. Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. *Biochem J.* 1971;124(5):58P.
97. Gregoriadis G, Jain S, Papaioannou I, et al. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. *Int J Pharm.* 2005;300(1–2):125–130.
98. Chuang YC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. *J Urol.* 2009;182(4):1393–1400.
99. Cockayne DA, Hamilton SG, Zhu QM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X₃-deficient mice. *Nature.* 2000;407(6807):1011–1015.
100. Vlaskovska M, Kasakov L, Rong W, et al. P2X₃ knock-out mice reveal a major sensory role for urothelially released ATP. *J Neurosci.* 2001;21(15):5670–5677.
101. Sun Y, Chai TC. Effects of dimethyl sulphoxide and heparin on stretch-activated ATP release by bladder urothelial cells from patients with interstitial cystitis. *BJU Int.* 2002;90(4):381–385.
102. Sun Y, Keay S, De Deyne PG, et al. Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. *J Urol.* 2001;166(5):1951–1956.
103. Sun Y, Chai TC. Up-regulation of P2X₃ receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. *J Urol.* 2004;171(1):448–452.
104. Sun Y, Chai TC. Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis. *Am J Physiol Cell Physiol.* 2006;290(1):C27–34.
105. Birdier LA, Barrick SR, Roppolo JR, et al. Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. *Am J Physiol Renal Physiol.* 2003;285(3):F423–429.
106. Erickson DR, Probert KJ. Pregnancy and interstitial cystitis/painful bladder syndrome. *Urol Clin North Am.* 2007;34(1):61–69.
107. Black LV, Ness TJ, Robbins MT. Effects of oxytocin and prolactin on stress-induced bladder hypersensitivity in female rats. *J Pain.* 2009;10(10):1065–1072.
108. Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. *Sci Transl Med.* 2012;4(143):143ra00.
109. Stenton GR, Mackenzie LF, Tam P, et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: part 1. Effects on inflammatory cell activation and chemotaxis *in vitro* and pharmacokinetic characterization *in vivo*. *Br J Pharmacol.* 2013;168(6):1506–1518.
110. Rajasekaran M, Locke KW, Parsons CL. MN-001, a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model. *BJU Int.* 2006;98(2):430–434.
111. Yoshimura N, Miyazato M, Kitta T, et al. Central nervous targets for the treatment of bladder dysfunction. *NeuroUrol Urodyn.* 2014;33(1):59–66.
112. Glazer EJ, Basbaum AI. Leucine enkephalin: localization in and axoplasmic transport by sacral parasympathetic preganglionic neurons. *Science.* 1980;208(4451):1479–1481.
113. Dray A, Nunan L, Wire W. Central delta-opioid receptor interactions and the inhibition of reflex urinary bladder contractions in the rat. *Br J Pharmacol.* 1985;85(3):717–726.
114. Yokoyama H, Sasaki K, Franks ME, et al. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin. *Hum Gene Ther.* 2009;20(1):63–71.
115. Yokoyama H, Oguchi T, Goins WF, et al. Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception. *Hum Gene Ther.* 2013;24(2):170–180.
116. Godfrey L, Yan L, Clarke GD, et al. Modulation of paracetamol antinociception by caffeine and by selective adenosine A₂ receptor antagonists in mice. *Eur J Pharmacol.* 2006;531(1–3):80–86.
117. Hussey MJ, Clarke GD, Ledent C, et al. Reduced response to the formalin test and lowered spinal NMDA glutamate receptor binding in adenosine A_{2A} receptor knockout mice. *Pain.* 2007;129(3):287–294.
118. Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: release and regulation of pain. *Prog Neurobiol.* 2003;69(5):313–340.
119. Miyazato M, Sugaya K, Nishijima S, et al. Intrathecal or dietary glycine inhibits bladder and urethral activity in rats with spinal cord injury. *J Urol.* 2005;174(6):2397–2400.
120. Miyazato M, Sugaya K, Nishijima S, et al. Changes of bladder activity and glycine levels in the lumbosacral cord after partial bladder outlet obstruction in rats. *Int J Urol.* 2008;15(9):843–847.
121. Nishijima S, Sugaya K, Fukuda T, et al. Serum amino acids as indicators of cerebrospinal neuronal activity in patients with micturition disorders. *Int J Urol.* 2006;13(12):1479–1483.
122. Zafra F, Gomez J, Olivares L, et al. Regional distribution and developmental variation of the glycine transporters

- GLYT1 and GLYT2 in the rat CNS. *Eur J Neurosci.* 1995;7(6):1342–1352.
123. Dohi T, Morita K, Kitayama T, et al. Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain. *Pharmacol Ther.* 2009;123(1):54–79.
 124. Haranishi Y, Hara K, Terada T, et al. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. *Anesth Analg.* 2010;110(2):615–621.
 125. Yoshikawa S, Oguchi T, Funahashi Y, et al. Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats. *Eur Urol.* 2012;62(4):704–712.
 126. Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. *J Rheumatol Suppl.* 2010;85:27–39.
 127. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. *Nat Rev Neurosci.* 2005;6(7):521–532.
 128. Schafers M, Svensson CI, Sommer C, et al. Tumor necrosis factor- α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. *J Neurosci.* 2003;23(7):2517–2521.
 129. Sommer C, Lindenlaub T, Teuteberg P, et al. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. *Brain Res.* 2001;913(1):86–89.
 130. Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. *Exp Neurol.* 1998;151(1):138–142.
 131. Fink DJ, Wechuck J, Mata M, et al. Gene therapy for pain: results of a phase I clinical trial. *Ann Neurol.* 2011;70(2):207–212.
 132. Behr-Roussel D, Gorny D, Mevel K, et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. *Eur Urol.* 2005;47(1):87–91.
 133. Bittencourt JA, Tano T, Gajar SA, et al. Relaxant effects of sildenafil on the human isolated bladder neck. *Urology.* 2009;73(2):427–430.
 134. Roehrborn CG, Kaminetsky JC, Auerbach SM, et al. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. *BJU Int.* 2010;105(4):502–507.
 135. Kitta T, Tanaka H, Mitsui T, et al. Type 4 phosphodiesterase inhibitor suppresses experimental bladder inflammation. *BJU Int.* 2008;102(10):1472–1476.
 136. Chen H, Wang F, Chen W, et al. Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of a randomized, double-blind, placebo-controlled trial—treatment of interstitial cystitis/painful bladder syndrome with low-dose sildenafil. *Urology.* 2014;84(1):51–56.
 137. van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. *Eur Urol.* 2008;53(1):60–67.
 138. Ueda T, Nakagawa M, Okamura M, et al. New cystoscopic diagnosis for interstitial cystitis/painful bladder syndrome using narrow-band imaging system. *Int J Urol.* 2008;15(12):1039–1043.
 139. Nickel JC, Irvine-Bird K, Jianbo L, et al. Phenotype-directed management of interstitial cystitis/bladder pain syndrome. *Urology.* 2014;84(1):175–179.

*** This study shows the classification of IC/BPS symptoms that can be used to develop the tailored approach for IC/BPS treatment.**

Affiliation

Teruyuki Ogawa^{1,2} MD, PhD, Osamu Ishizuka² MD, PhD, Tomohiro Ueda³ MD, PhD, Pradeep Tyagi¹ PhD, Michael B Chancellor⁴ MD, & Naoki Yoshimura^{†1} MD, PhD

[†]Author for correspondence

¹Department of Urology, University of Pittsburgh, School of Medicine, Suite 700 Kaufmann Medical Building, 3471 Fifth Ave., Pittsburgh, PA 15213, USA

Tel.: 412-692-4137;

Fax: 412-692-4380;

nyos@pitt.edu

²Department of Urology, School of Medicine, Shinshu University, Matsumoto, Japan

³Department of Urology, Ueda Clinic, Kyoto, Japan

⁴Department of Urology, Oakland University, William Beaumont School of Medicine, Royal Oak, MI, USA

The Journal of Urology

Liposome-based Intravesical Therapy targeting Nerve Growth Factor (NGF) ameliorates Bladder Hypersensitivity in Rats with Experimental Colitis --Manuscript Draft--

Manuscript Number:	
Article Type:	Investigative Urology Article
Full Title:	Liposome-based Intravesical Therapy targeting Nerve Growth Factor (NGF) ameliorates Bladder Hypersensitivity in Rats with Experimental Colitis
First Author:	NAOKI KAWAMORITA
Corresponding Author:	Naoki Yoshimura, MD, PhD University of Pittsburgh Pittsburgh, PA UNITED STATES
Corresponding Author E-Mail:	nyos@pitt.edu
Corresponding Author's Institution:	University of Pittsburgh
Order of Authors:	NAOKI KAWAMORITA Satoru Yoshikawa Mahendra Kashyap Pradeep Tyagi Yoichi Arai Michael B. Chancellor Naoki Yoshimura, MD, PhD
Manuscript Region of Origin:	UNITED STATES
Keywords:	Chronic pelvic pain syndrome, Irritable bowel syndrome, Bladder pain syndrome, interstitial cystitis, Liposome, Nerve growth factor, Antisense
Manuscript Classifications:	20: Basic Science/Research; 20.140: Physiology
Abstract:	<p>Purpose: Pelvic organ cross sensitization is considered to contribute to overlapping symptoms in CPPS. Overexpression of NGF in the bladder is reportedly involved in the symptom development of BPS/IC patients. This study examined whether a reduction of overexpressed NGF in the bladder by intravesical treatment with liposome and OND conjugates ameliorates bladder hypersensitivity in a rat colitis model.</p> <p>Materials and Methods: Adult female rats were divided into; (a) a control group, (b) a colitis-OND group with intracolonic TNBS enema and intravesical liposomal-OND treatments, (c) a colitis-saline group with intracolonic TNBS and intravesical saline treatments, (d) a sham-OND group with intravesical liposomal-OND treatment without colitis and (e) a sham-saline group with intravesical saline treatment without colitis. Liposomes conjugated with NGF antisense OND or saline solution were instilled into the bladder, and 24 hours later, colitis was induced by TNBS enema. Effects of NGF antisense treatment were evaluated by pain behavior, cystometry, molecular analyses and immunohistochemistry 10 days after TNBS treatment.</p> <p>Results: In colitis-saline rats, pain behavior was enhanced compared to other 4 groups including colitis-OND rats, and intercontraction intervals were significantly reduced by acetic acid stimulation as opposed to slight decreases in other groups. NGF expression in the bladder mucosa was higher in the colitis-saline group than in other groups.</p> <p>Conclusions: NGF overexpression in the bladder mucosa and bladder hypersensitivity induced after colitis were reduced by intravesical application of liposomal OND targeting NGF, suggesting that the local anti-NGF therapy could be effective for the treatment of bladder symptoms in CPPS.</p>
Author Comments:	
Suggested Reviewers:	Anna Malykhina

	Associate Professor , University of Colorado School of Medicine Anna.Malykhina@ucdenver.edu
	Célia Cruz Faculty of Medicine of Porto ccruz@med.up.pt
Opposed Reviewers:	

Liposome-based Intravesical Therapy targeting Nerve Growth Factor (NGF)

ameliorates Bladder Hypersensitivity in Rats with Experimental Colitis

Naoki Kawamorita^{1,2}, Satoru Yoshikawa¹, Mahendra Kashyap¹, Pradeep Tyagi¹, Yoichi

Arai², Michael B. Chancellor³, Naoki Yoshimura^{1,*}

1, Department of Urology, University of Pittsburgh School of Medicine, Suite 700, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA

2, Department of Urology, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan

3, Department of Urology, Oakland University William Beaumont School of Medicine, Royal Oak, MI 48073, USA

*Corresponding author: Naoki Yoshimura

Department of Urology, University of Pittsburgh School of Medicine,

Suite 700, Kaufmann Medical Building

3471 Fifth Ave., Pittsburgh, Pennsylvania 15213

TEL: 412-692-4137

FAX: 412-692-4380

E-mail: nyos@pitt.edu

Runninghead: Colitis in rat model augmented pain sensation with NGF overexpression in the bladder. Intravesical treatment with liposomal-antisense targeting NGF attenuated bladder hypersensitivity.

Key words: Chronic pelvic pain syndrome, Irritable bowel syndrome, Bladder pain syndrome, interstitial cystitis, Liposome, Nerve growth factor, Antisense

Abstract

Purpose: Pelvic organ cross sensitization is considered to contribute to overlapping symptoms in CPPS. Overexpression of NGF in the bladder is reportedly involved in the symptom development of BPS/IC patients. This study examined whether a reduction of overexpressed NGF in the bladder by intravesical treatment with liposome and OND conjugates ameliorates bladder hypersensitivity in a rat colitis model.

Materials and Methods: Adult female rats were divided into; (a) a control group, (b) a colitis-OND group with intracolonic TNBS enema and intravesical liposomal-OND treatments, (c) a colitis-saline group with intracolonic TNBS and intravesical saline treatments, (d) a sham-OND group with intravesical liposomal-OND treatment without colitis and (e) a sham-saline group with intravesical saline treatment without colitis. Liposomes conjugated with NGF antisense OND or saline solution were instilled into the bladder, and 24 hours later, colitis was induced by TNBS enema. Effects of NGF antisense OND treatment were evaluated by pain behavior, cystometry, molecular analyses and immunohistochemistry 10 days after TNBS treatment.

Results: In colitis-saline rats, pain behavior was enhanced compared to other 4 groups including colitis-OND rats, and intercontraction intervals were significantly reduced by acetic acid stimulation as opposed to slight decreases in other groups. NGF expression in the bladder mucosa was higher in the colitis-saline group than in other groups.

47 Conclusions: NGF overexpression in the bladder mucosa and bladder hypersensitivity
48 induced after colitis were reduced by intravesical application of liposomal OND
49 targeting NGF, suggesting that the local anti-NGF therapy could be effective for the
50 treatment of bladder symptoms in CPPS.

51

52 250 words

53

54

Introduction

Chronic pelvic pain syndrome (CPPS) including bladder pain syndrome/interstitial cystitis (BPS/IC) and irritable bowel syndrome (IBS) is defined as a disease entity with painful symptoms in the pelvic region that last for at least six months and presents a major challenge to patients and health care providers ^{1,2}. Symptoms of BPS/IC and IBS are often overlapped as one-third of patients diagnosed with BPS/IC exhibit symptoms consistent with IBS, while 25-56% of patients diagnosed with IBS also have symptoms of BPS/IC ^{3,4}. In order to explain this complex pathology, pelvic organ “cross sensitization” has been proposed to contribute to the clinically overlapping symptoms of CPPS ⁵. We also recently demonstrated that rats with experimental colitis exhibit enhanced pain sensitivity in the bladder as evidenced by enhanced freezing behavior induced by intravesical nociceptive stimulation ⁶.

Nerve growth factor (NGF) is known to be a complex regulator of sensory afferent plasticity in response to injury or inflammation ^{7,8}. Increased levels of NGF are found in urine obtained from BPS/IC patients ⁹, and a recent meta-analysis study reported that urinary NGF could be a useful biomarker for the diagnosis of BPS/IC as well as a predictive biomarker to help guide treatments ¹⁰. We also recently reported that instillation of liposomes conjugated with antisense oligonucleotide (OND) targeting

NGF into the bladder suppressed bladder overactivity in a rat model of acute cystitis ¹¹. However, it is still unknown if NGF contributes to bladder overactivity and enhanced bladder pain sensitivity after colonic inflammation. Therefore, this study investigated whether intravesical liposomal-OND treatment can suppress NGF expression in the bladder and bladder hypersensitivity in a rat model of experimental colitis.

Materials and Methods

Animal model: Experiments were performed in accordance with NIH guidelines, and the protocol was approved by the University of Pittsburgh Institutional Animal Care and Use Committee. Adult female Sprague-Dawley rats were used and divided into 5 groups; (1) a control group (no treatment), (2) a colitis-OND group with intracolonic 2,4,6-trinitrobenzen sulfonic acid (TNBS) enema and intravesical liposomal-OND treatments, (3) a colitis-saline group with intracolonic TNBS and intravesical saline treatments, (4) a sham-OND group with intravesical liposomal-OND treatment without colitis and (5) a sham-saline group with intravesical saline treatment without colitis..

Liposome-conjugated NGF antisense instillation: At 24hr before injection of TNBS (day 0), rats were anesthetized with 2% isoflurane (Baxter Inc., IL), and catheterized

through the urethra into the bladder using a 24-gauge angiocatheter. After draining urine from the bladder, 12 μ M of phosphorothioated NGF antisense OND with the sequence 5'GCCCCGAGACGCCTCCCGA 3' complexed with liposomes or saline (vehicle) in a volume of 0.2ml was instilled (n=6 in each group) as we previously described¹¹. Rats were then allowed to recover from anesthesia.

Colitis model; Colitis was induced by administration of TNBS solution (50mg/ml), which was prepared by mixing 1ml of TNBS, 1.93ml of H₂O and 2.93ml of ethanol.

Rats were fasted for 24 hours before instillation, anesthetized with 2% isoflurane and inserted with a polyethylene catheter attached to a 1-ml syringe into the colon 6 cm proximal to the anus. The lower body of rats was elevated by lifting the tale, and TNBS or vehicle solution in a volume of 0.5ml was injected and kept for 3 minutes (day 1).

Conscious Cystometry: Twenty-seven rats (5 or 6 rats per group) were used for cystometric evaluation. After anesthesia with 2 % isoflurane, laparotomy through a lower abdominal incision was performed and a PE 50 tube (Scientific Commodities Inc., AZ, USA) with the distal end sealed by heat was inserted into the bladder dome as a cystostomy catheter. The catheter was tunneled subcutaneously and placed underneath

the back skin 3 days before cystometry (CMG). Thereafter, the abdomen was closed with running sutures.

Ten days after TNBS or vehicle treatment, rats were anesthetized with 2 % isoflurane and a distal end of cystostomy tube was exteriorized from the subcutaneous space. After recovery from anesthesia, rats were placed in restraining cages (Yamanaka Chemical Ind., Japan). The cystostomy catheter was connected through a three-way stopcock to a pressure transducer (BLPR2, World Precision Instruments, Inc., Sarasota, FL, USA) and to a syringe pump (Harvard Apparatus, Holliston, MA, USA). After rats were acclimated in a cage for 1 hour, CMG was performed by filling the bladder with physiological saline (0.04ml/min) to elicit repetitive voiding. The intravesical pressure was recorded using data-acquisition software (sampling rate was 400 Hz. Chart, AD Instruments, Colorado Springs, CO, USA) on a computer system (Power Lab, AD Instruments). During CMG, at least 10 reproducible micturition cycles were recorded after an initial stabilization period (15-30min). Intercontraction intervals (ICIs), which are the time between 2 consecutive micturition cycles, were measured 30 min after saline infusion or 60 min after acetic acid (AA) infusion and averaged from at least 3 ICIs.

Nociceptive behavioral study: Twenty-four rats (4-5 rats per group) were used for analyses of nociceptive behavior induced by bladder irritation, as previously described¹². Briefly, rats were acclimated in metabolic cages (Nalgene, Rochester, NY, USA) for 3 h. Water (30ml/kg) was then administered orally, and after 15 min, animals placed in a Bollman cage were instilled with resiniferatoxin (RTX; 0.3 μ M, 0.3 ml) into the bladder via a temporally inserted urethral catheter (PE-50) for 1 min. Thereafter, the urethral catheter was removed, and rats were placed back to metabolic cages, and licking and freezing behaviors were scored for a period of 15 min with 5-s intervals¹².

Quantification of messenger RNA: Twenty five rats (n=5 in each group) were used to measure mRNA and protein levels of NGF. The bladder was harvested at day 10 after TNBS or vehicle was given. The bladder was separated into mucosal and detrusor layers under a microscope. Total RNA was extracted by using the Rneasy kit (Quagen, Hilden, Germany), and 2 μ g of total RNA was reverse-transcribed into complementary DNA using the ThermoScript RT-PCR System (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. Quantitative polymerase chain reaction (PCR) was performed with an Mx3000P Real-Time PCR System (Stratagene, La Jolla, CA, USA) in a 25 μ l volume using SYBR Green PCR Master Mix (QIAGEN,

Valencia, CA, USA). Amplification of cDNA was performed using OND primers specific for NGF or β 2MG as a control gene. OND primer sequences were as follows:

5'-TCCACCCACCCAGTCTTCCA-3' (forward, NGF),
 5'-GCCTTCCTGCTGAGCACACA-3' (reverse, NGF),
 5'-GACCGATGTATATGCTTGCAGAGT-3' (forward, β 2MG),
 5'-GGATCTGGAGTTAACTGGTCCAG -3' (reverse, β 2MG). The protocol consisted of 40 replication cycles.

Measurement of NGF protein level: Eighteen rats (3-4 rats in each group) were used. The bladder was divided into mucosal and detrusor layers. Tissues were homogenized in RIPA lysis buffer system (Santa Cruz Biotechnology Inc., USA) in the presence of 1mM Na_3VO_4 , 2mM PMSF and 10 μ L/mL protease inhibitor. Protein concentration was measured by using Pierce BCA protein Assay kit (Thermo Scientific, USA). Lysates of separated mucosa and detrusor tissues were stored at -80°C until assays. The samples were assayed in duplicate using enzyme-linked immunoabsorbent assay (ELISA) kit (Promega, Madison, WI, USA), according to the manufacturer's instruction, and ELISA plates were read at 450 nm wave on an Elx800 microplate reader (Bio-Tek Instruments, Winooski, VT, USA). Tissue NGF values were normalized against protein

concentrations of each sample and expressed as picograms per microgram protein.

Immunohistochemistry: Ten days after TNBS or vehicle treatment, rats were perfused transcardially with cold physiological saline containing heparin sodium (1 unit/ml) followed by cold 4 % paraformaldehyde solution in 0.1M phosphate buffer (PFA). Then the bladder was harvested and post-fixed in 4% PFA at 4 °C for 24 h and soaked in the 20 % sucrose overnight at 4°C. The frozen tissues were then cut at 10 µm thickness (transverse sections) and mounted onto slides. Immunohistochemical staining was performed by using Dako EnVision+ System-HRP Labelled Polymer (Dako Cytomation, Glostrup, Denmark) with anti-NGF antibodies (1:250; sc-548, Santa-Cruz, Heidelberg, Germany). An antigen retrieval was performed in the regent of HistVTone at 70°C (Nacalai, Kyoto, Japan) for 20 min. Background activities were blocked with the blocking agent (Dako, Glostrup, Denmark) at room temperature for 1 h. Reaction products were visualized by Liquid DAB+ Substrate Chromogen System (Dako, Denmark).

Statistical analysis: The data were expressed as mean ± SEM and were analyzed using GraphPad Prism 6.0 statistical software (San Diego, CA). Statistical differences among

groups were determined by one-way ANOVA followed by Turkey's post-hoc test. A statistical comparison of mean values between two groups was performed using Mann-Whitney test with Bonferroni correction. P values less than 0.05 were considered to be statistically significant.

Results

Nociceptive behavior: The number of licking behavior events in the colitis-vehicle group was significantly higher than that in the control group, whereas there was no significant difference in licking behavior score compared to other 3 groups including the colitis-OND group (Figure 1A). In contrast, the number of freezing events in the colitis-vehicle group was higher than that in other groups. These results indicate that the increase of freezing events, but not licking events, after colitis was prevented in the colitis-OND group to the same level as in sham groups (Figure 1B).

Cystometry: There was no significant difference in ICIs among groups before 0.1 % AA infusion (Figure 2 A). The reduction rate of ICIs after AA infusion in the colitis-vehicle group was significantly greater than those in colitis-OND and sham-vehicle groups (one-way ANOVA followed by Turkey's post-hoc test) and those

in control and sham-OND groups (Mann-Whitney test) (Figure 2 B).

Quantitative mRNA analysis of NGF in the bladder mucosa and detrusor: The mRNA expression of NGF in the bladder mucosa in the colitis-vehicle group was significantly higher compared to the colitis-OND group (one-way ANOVA followed by Turkey's post-hoc test) (Figure 3A). In addition, there was a tendency of increased NGF mRNA expression in the detrusor of colitis-vehicle rats vs. saline-vehicle rats although the difference was not significant (one-way ANOVA), and no reduction was seen in the detrusor NGF expression of colitis-OND rats compared to colitis-vehicle rats (Figure 3B).

NGF protein levels in the bladder mucosa and detrusor: The protein level of NGF in the bladder mucosa in the colitis-vehicle group was significantly higher than those in control, colitis-OND and sham-OND groups (Figure 4A). There was no significant difference in NGF protein levels of the detrusor among groups (Figure 4B).

Immunohistochemistry of NGF expression: Immunohistochemical staining of the bladder for NGF showed a high level of positive staining in the bladder urothelial layer

of the colitis-vehicle group in contrast to faint staining in control and colitis-OND groups (Figure 5 b, a and c, respectively). The positive NGF staining in the detrusor layer was seen in control, colitis-vehicle and colitis-OND groups at similar levels (Figure 5).

Discussion

The results of our study demonstrated that: (1) rats with TNBS-induced colitis exhibited enhanced bladder pain sensitivity and bladder overactivity in response to nociceptive bladder stimuli using intravesical infusion of RTX and AA, respectively, (2) TNBS-induced colitis increased NGF expression in the bladder mucosa and (3) intravesical instillation of liposomes with antisense OND targeting NGF ameliorated bladder pain behavior and bladder overactivity in association with a reduction of NGF overexpression in the bladder mucosa.

This study confirmed our previous findings that freezing and licking behaviors, which predominantly correspond to bladder and urethral pain induced by activation of bladder and urethral afferent pathways, respectively¹²⁻¹⁴, are enhanced after colitis (i.e., enhanced pain behavior in the colitis-saline group vs. the control group)⁶. We also further demonstrated that colitis induces bladder overactivity as evidenced by the

significantly larger reduction in ICIs after AA stimulation in the colitis-saline group vs. the control or saline-vehicle group. Because, in our previous study, increased myeloperoxidase activity, which correlates with tissue neutrophil infiltration, was found in the colon, but not in the bladder or urethra, following TNBS-induced colitis⁶, it is assumed that increased bladder pain sensitivity in rats with TNBS-induced colitis is produced by the indirect mechanism in the lower urinary tract other than inflammatory changes directly elicited by TNBS administered into the colon.

Previous studies reported that pelvic organ cross sensitization is induced by activation of dichotomized afferents innervating different pelvic organs and that activation of nociceptive C-fiber afferents in one organ (e.g., colon) could sensitize afferent pathways in another organ (e.g., bladder) to release neuropeptides such as substance P that trigger neurogenic inflammation and mast cell activation^{6, 15, 16}. This study further demonstrated that the colon-to-bladder cross sensitization after colitis also induces overexpression of NGF in the bladder mucosa including the urothelial layer (Figs. 3 & 4) and that urothelially expressed NGF after colitis is a key mediator that increases bladder pain sensitivity because intravesical treatment with liposome and NGF antisense conjugates significantly reduces bladder pain behavior (i.e., freezing behavior) (Fig. 1) and bladder overactivity induced by nociceptive stimuli in the bladder

(Fig. 2). Previous clinical studies showed that urinary NGF could be a useful biomarker for the diagnosis of BPS/IC^{9, 10}. NGF has also been highlighted as a chemical mediator in experimental animal models of bladder hypersensitivity¹⁷⁻¹⁹, and chronic administration of NGF into the bladder wall or into the spinal cord induced bladder overactivity and increased excitability of bladder afferent neurons in rats²⁰⁻²². Thus, NGF overexpression in the bladder mucosa induced by the colon-to-bladder cross sensitization following colitis is likely to stimulate bladder afferent pathways to enhance bladder pain sensitivity.

In clinical studies, monoclonal NGF antibody was systemically administered to treat the symptoms in patients with BPS/IC or other chronic pain syndromes²³. In these studies, systemic adverse events including headache, hyperesthesia, abnormal peripheral sensation and dizziness have been reported as obstacles for the systemic NGF antibody therapy to become a feasible treatment of pain, although some studies showed therapeutic effects on pain symptoms²³. Thus, the intravesical therapy targeting NGF expressed in the bladder could be an alternate option for the treatment of BPS/IC. We have previously shown that liposomal application is necessary to deliver NGF antisense OND to the bladder urothelium to suppress NGF overexpression and bladder overactivity in a rat model of acute cystitis¹¹. In addition, Chuang et al. reported that

intravesical application of empty liposomes significantly decreased painful and urinary urgency symptoms in 24 BPS/IC patients²⁴. Recent clinical studies have also demonstrated that the intravesical treatment using liposome-encapsulated onabotulinum toxin-A significantly improved symptoms in patients with overactive bladder without severe adverse events^{25,26}. Therefore, local suppression of NGF in the bladder using intravesical liposome-based delivery techniques could be an attractive approach for the treatment of bladder symptoms, while avoiding systemic side effects, in patients with BPS/IC and IBS.

Conclusion

We showed that intravesical treatment with liposome and NGF antisense conjugates reduced NGF overexpression in the bladder and attenuated bladder hypersensitivity in a rat colitis model. Therefore, the liposome-based antisense treatment targeting NGF in the bladder could be a new, effective modality for the treatment of bladder pain in CPPS patients, in whom the cross-sensitization mechanism is involved in the emergence of overlapping symptoms from different pelvic organs.

Acknowledgement

291 This work was supported by grants from DOD (W81XWH-12-1-0565) and NIH
292 (DK088836 and P01DK093424).

References

1. Engeler, D. S., Baranowski, A. P., Dinis-Oliveira, P. et al.: The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. *Eur Urol*, **64**: 431, 2013
2. Hanno, P. M., Burks, D. A., Clemens, J. Q. et al.: AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. *The Journal of urology*, **185**: 2162, 2011
3. Alagiri, M., Chottiner, S., Ratner, V. et al.: Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. *Urology*, **49**: 52, 1997
4. Novi, J. M., Jeronis, S., Srinivas, S. et al.: Risk of irritable bowel syndrome and depression in women with interstitial cystitis: a case-control study. *The Journal of urology*, **174**: 937, 2005
5. Pezzone, M. A., Liang, R., Fraser, M. O.: A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. *Gastroenterology*, **128**: 1953, 2005
6. Yoshikawa, S., Kawamorita, N., Oguchi, T. et al.: Pelvic organ cross-sensitization to enhance bladder and urethral pain behaviors in rats with experimental colitis. *Neuroscience*, **284**: 422, 2015
7. Freund, V., Frossard, N.: [Nerve growth factor (NGF) in inflammation and asthma]. *Rev Mal Respir*, **21**: 328, 2004
8. Kim, J. S., Kang, J. Y., Ha, J. H. et al.: Expression of nerve growth factor and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in asthmatic patients. *The Journal of asthma : official journal of the Association for the Care of Asthma*, **50**: 712, 2013
9. Okragly, A. J., Niles, A. L., Saban, R. et al.: Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. *The Journal of urology*, **161**: 438, 1999
10. Qu, H. C., Zhang, W., Yan, S. et al.: Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis. *PloS one*, **9**: e106321, 2014
11. Kashyap, M., Kawamorita, N., Tyagi, V. et al.: Down-regulation of nerve growth factor expression in the bladder by antisense oligonucleotides as new treatment for overactive bladder. *The Journal of urology*, **190**: 757, 2013
12. Saitoh, C., Chancellor, M. B., de Groat, W. C. et al.: Effects of intravesical instillation

- of resiniferatoxin on bladder function and nociceptive behavior in freely moving, conscious rats. *The Journal of urology*, **179**: 359, 2008
13. Funahashi, Y., Oguchi, T., Goins, W. F. et al.: Herpes simplex virus vector mediated gene therapy of tumor necrosis factor- α blockade for bladder overactivity and nociception in rats. *The Journal of urology*, **189**: 366, 2013
14. Yokoyama, H., Oguchi, T., Goins, W. F. et al.: Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception. *Hum Gene Ther*, **24**: 170, 2013
15. Malykhina, A. P., Qin, C., Greenwood-van Meerveld, B. et al.: Hyperexcitability of convergent colon and bladder dorsal root ganglion neurons after colonic inflammation: mechanism for pelvic organ cross-talk. *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society*, **18**: 936, 2006
16. Fitzgerald, J. J., Ustinova, E., Koronowski, K. B. et al.: Evidence for the role of mast cells in colon-bladder cross organ sensitization. *Auton Neurosci*, **173**: 6, 2013
17. Jaggar, S. I., Scott, H. C., Rice, A. S.: Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent. *Br J Anaesth*, **83**: 442, 1999
18. Chae, C. H., Lee, H. C., Jung, S. L. et al.: Swimming exercise increases the level of nerve growth factor and stimulates neurogenesis in adult rat hippocampus. *Neuroscience*, **212**: 30, 2012
19. Merrill, L., Malley, S., Vizzard, M. A.: Repeated variate stress in male rats induces increased voiding frequency, somatic sensitivity, and urinary bladder nerve growth factor expression. *American journal of physiology. Regulatory, integrative and comparative physiology*, **305**: R147, 2013
20. Lamb, K., Gebhart, G. F., Bielefeldt, K.: Increased nerve growth factor expression triggers bladder overactivity. *The journal of pain : official journal of the American Pain Society*, **5**: 150, 2004
21. Yoshimura, N., Bennett, N. E., Hayashi, Y. et al.: Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, **26**: 10847, 2006
22. Zvara, P., Vizzard, M. A.: Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. *BMC physiology*, **7**: 9, 2007
23. Evans, R. J., Moldwin, R. M., Cossons, N. et al.: Proof of concept trial of tanezumab

- 364 for the treatment of symptoms associated with interstitial cystitis. The Journal of
365 urology, **185**: 1716, 2011
- 366 24. Chuang, Y. C., Lee, W. C., Chiang, P. H.: Intravesical liposome versus oral pentosan
367 polysulfate for interstitial cystitis/painful bladder syndrome. The Journal of urology,
368 **182**: 1393, 2009
- 369 25. Kuo, H. C., Liu, H. T., Chuang, Y. C. et al.: Pilot study of liposome-encapsulated
370 onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur
371 Urol, **65**: 1117, 2014
- 372 26. Chuang, Y. C., Kaufmann, J. H., Chancellor, D. et al.: Bladder Instillation of
373 Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder
374 Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial. The
375 Journal of urology, 2014
- 376

Figure legends

Figure1. The number of nociceptive behavior events, licking (A) and freezing (B), induced by intravesical injection of resiniferatoxin (RTx).

(A) The number of licking behavior events in the colitis-saline group was significantly higher than that in the control group, whereas there was no difference in licking score compared to other 3 groups. (B) Freezing behavior events in the colitis-saline group were increased significantly, compared to controls; however, the increase of freezing events was significantly decreased in the colitis-OND group to the same level as in sham-groups. . *: $p < 0.05$, **: $p < 0.01$ (compared to each group; one-way ANOVA followed by Turkey's post-hoc test)

Figure2. Effects of intravesical infusion with acetic acid (AA) on intercontraction intervals (ICIs) in cystometry. (A) ICIs before AA infusion. (B) The reduction ratio of ICIs after AA infusion to ICIs before AA infusion.

There was no significant difference in ICIs before AA infusion among groups (A). The ICI reduction rate after AA infusion in the colitis-saline group was significantly higher than that in the colitis-OND group (B). * $P < 0.05$ (one-way ANOVA followed by Turkey's post-hoc test). # $P < 0.05$ (compared to the colitis-vehicle group;

Mann-Whitney test).

Figure 3. mRNA expression of NGF in the bladder mucosa (A) and detrusor (B) 10 days after intracolonic injection of TNBS or vehicle (50 % ethanol). * $P < 0.05$ (one-way ANOVA followed by Turkey's post-hoc test).

Figure 4. Protein expression of NGF in the bladder mucosa (A) and detrusor (B) 10 days after intracolonic injection of TNBS or vehicle (50 % ethanol). * $P < 0.05$ (compared to each group; one-way ANOVA followed by Turkey's post-hoc test).

Figure 5. Photomicrographs of NGF staining in the rat bladder. There was increased positive staining for NGF in the urothelial layer of the colitis-saline group (B,b), in contrast to faint staining in the mucosal layer of the bladder from the control group (A,a) and the colitis-OND group (C,c). Magnification of pictures (A,B,C) and (a,b,c) is $\times 100$ and $\times 400$, respectively. The magnified areas of picture A, B and C, which are shown in pictures a, b and c, respectively, are indicated by rectangular boxes.

Abbreviations

NGF = nerve growth factor

CPPS = chronic pelvic pain syndrome

OND = oligonucleotide


BPS/IC = bladder pain syndrome/interstitial cystitis

IBS = irritable bowel syndrome

TNBS = intracolonic 2,4,6-trinitrobenzen sulfonic acid

Figure 1

A Licking Behavior



B Freezing Behavior




Figure 2




Figure 3




Figure 4





Figure 5


Immunohistochemistry






Control



Colitis-saline



Colitis -OND



LIPOSOME-BASED INTRAVESICAL THERAPY TARGETING NERVE GROWTH FACTOR (NGF) AMELIORATES BLADDER HYPERSENSITIVITY IN RATS

Background: It has recently been proposed that pelvic organ “cross sensitization” contributes to the clinically overlapping symptoms in irritable bowel syndrome (IBS) and interstitial cystitis/bladder pain syndrome (IC/BPS). Overexpression of nerve growth factor (NGF) in the bladder is thought to be one of the key factors in the symptom development in IC/BPS patients. We hereby explore whether bladder hypersensitivity induced by experimental colitis and NGF overexpression in the bladder are induced after colitis and whether intravesical administration of NGF antisense-liposome solution (liposomal-OND) treatment can suppress bladder hypersensitivity and NGF expression in a rat model with experimental colitis.

Methods: Adult female SD rats were used; (a) control group, (b) colitis-OND group (intracolonic 2,4,6-trinitrobenzen sulfonic acid [TNBS] enema and intravesical liposomal OND were given), (c) colitis-saline group (intracolonic TNBS and intravesical saline were given), (d) sham-OND group (intravesical liposomal OND was given without colitis) and (e) sham-saline group (intravesical saline was given without colitis). Intravesical administration of liposomal-OND: Under isoflurane anesthesia, 0.2ml of either liposomal-OND or saline was instilled to the bladder through an inserted urethral catheter. Experimental colitis model: Twenty-four hours after instillation of liposomal-OND or saline and fasting, colitis was induced by the enema of 30mg TNBS dissolved in 50% ethanol through a polyethylene catheter inserted 8 cm proximal to the anus in a head-down position. Ten days after liposomal-OND or saline injection, animals were subjected to either in vivo studies or bladder tissue removal. Assessment included nociceptive behaviour testing in response to 1 -min intravesical administration of resiniferatoxin (RTX), awake cytometry with saline followed by 0.1% acetic acid (AA) were continuously infused to evaluate changes in intracontraction intervals (ICIs) in conscious rats and immunohistochemistry with NGF antibody and qPCR molecular analysis of NGF.

Results: In the colitis-saline group, the score of freezing behaviour was significantly higher than that of all other groups including the colitis-OND group. The score of licking behavior in the colitis-saline group was significantly higher than in the control group and tended to higher compared to other 3 groups without significant differences. ICIs before intravesical AA stimulation were not different among groups; however, the ICI reduction rate after AA instillation into the bladder was significantly higher in the colitis-saline group than that in the colitis-OND group. There was increased immunoreactivity of NGF in the bladder mucosa in the colitis-saline group, whereas there was only faint staining in the control and colitis-OND groups. The mRNA expression of NGF in the colitis-saline group was significantly increased in the mucosa compared to control and colitis OND groups. In addition the protein level of NGF in the mucosa was also higher in the colitis-saline group compared to other groups.

Conclusion: The liposome-based antisense treatment targeting NGF in the bladder could be a new, effective modality for the treatment of bladder pain and overactivity in chronic pelvic pain syndrome patients including those with IC/BPS, in whom the pelvic organ “cross sensitization” mechanism is involved in overlapping symptoms from different pelvic organs.

Majima T¹, Tyagi P², Dogishi K³, Kadekawa K⁴, Kashyap M², Wada N⁵, Takai S⁶, Shimizu T⁷, Gotoh M⁸, Chancellor M⁹, Yoshimura N²

1. University of Pittsburgh, Nagoya University Graduate School of Medicine, 2. University of Pittsburgh, 3. Graduate School of Pharmaceutical Sciences, Kyoto University,, 4. University of Pittsburgh, Southern Knights' Laboratory LLP, 5. University of Pittsburgh, Asahikawa Medical University, 6. University of Pittsburgh, Nagoya University Graduate School of Medicine, 7. University of Pittsburgh, Kochi Medical School, Kochi University, 8. Nagoya University Graduate School of Medicine, 9. William Beaumont Oakland University School of Medicine

THE EFFECT OF INTRAVESICAL LIPOSOME-BASED NGF ANTISENSE THERAPY ON BLADDER OVERACTIVITY AND NOCICEPTION IN A RAT MODEL OF CYSTITIS INDUCED BY HYDROGEN PEROXIDE

Hypothesis / aims of study

Nerve growth factor (NGF) has been proposed to be an important mediator for inducing hyperexcitability of afferent pathways that contributes to pain and storage symptoms of interstitial cystitis/bladder pain syndrome (IC/BPS). A previous clinical study indicated that systemic application of NGF monoclonal antibody significantly reduced pain/urgency in IC/BPS patients, but its systemic adverse events such as paresthesia and hyperesthesia were a critical issue [1]. Therefore, the site-specific reduction of NGF would be desirable to reduce the intrinsic toxicity from systemic blockade of NGF. In this regard, our previous study demonstrated that intravesical liposome-based NGF antisense therapy significantly improved bladder overactivity in a rat model of acute cystitis induced by intravesical application of acetic acid [2]. However, it still remains unclear whether local NGF antisense therapy has a chronic effect. Therefore, we investigated the effect of intravesical liposome-based NGF antisense therapy on bladder overactivity and nociceptive behaviour in a rat model of chronic cystitis induced by hydrogen peroxide (HP).

Study design, materials and methods

Adult Sprague-Dawley female rats were used according to the experimental protocol approved by the Institutional Animal Care and Use Committee.

- 1) 1.5% HP was administered into the bladder on day 0. Liposomes conjugated with NGF antisense tagged with TYE563 fluorescent protein was given into the bladder on day 2. The expression of TYE563 was observed under a fluorescent microscope on day 3.
- 2) In another set of experiments, rats were divided into 4 groups: a) saline + vehicle (SV) group, b) saline + liposome-NGF antisense (SN) group, c) 1.5% HP + vehicle (HV) group, d) 1.5% HP + liposome-NGF antisense (HN) group. Saline or 1.5% HP was administered into the bladder on day 0. Each rat was treated with intravesical vehicle or NGF antisense administration on day 2. Continuous cystometry (CMG) was performed in an awake condition on day 7.
- 3) Nociceptive behaviours induced by 1-min intravesical instillation of resiniferatoxin (TRPV1 agonist, RTx) such as licking behaviour (lower abdominal licking) and freezing behaviour (motionless head-turning towards lower abdomen) was observed on day 7.
- 4) After rats were intracardially perfused with cold heparinised-saline, followed by 4% paraformaldehyde, the bladder and L6 DRG were removed on day 7. Haematoxylin-Eosin (HE) staining as well as immunofluorescence staining for NGF were performed.
- 5) Bladder tissue was harvested on day 7. The mRNA expression of NGF, TRPV1 and brain-derived neurotrophic factor (BDNF) was measured by RT-PCR.

Results

- 1) TYE563 expression was observed in the bladder urothelium 1 day after intravesical application of TYE563- tagged liposome-NGF antisense conjugates.
- 2) In CMG, the HV group showed significantly ($p=0.001$) shorter intercontraction intervals (ICI) than the SV group (ICI: 442 ± 64 and 889 ± 73 sec, respectively). The HN group showed significantly ($p=0.007$) longer ICI than the HV group (ICI: 711 ± 46 and 442 ± 64 , respectively). There was no significant difference in ICI between SV and SN groups ($p=0.56$, Fig.1.)
- 3) There were no significant differences in licking behaviour among 4 groups. However, the number of freezing events was significantly ($p=0.002$) higher in the HV group than in the SV group (18 ± 2 and 6 ± 1 events for 15 min after RTx treatment, respectively). The HN group showed the significantly ($p=0.04$) less number of freezing events than the HV group (9 ± 3 and 18 ± 2 events, respectively.) There was no significant difference in the number of freezing events between the SV and SN group (Fig.2.)
- 4) HE staining showed that there were substantial infiltration of the inflammatory cells, submucosal bleeding, and detrusor hypertrophy in the bladder wall in the HV group compared with SV group, which were alleviated in the HN group. Immunofluorescence staining indicated that the expression of NGF protein in the mucosa ($p=0.02$) and L6 DRG ($p=0.01$) was significantly higher in the HV group than in the SV group. On the other hand, the HN group indicated significantly lower expression of NGF protein in the mucosa ($p=0.002$) and L6 DRG ($p=0.01$) than the HV group (Fig.3 and 4.) In the detrusor, there was no significant difference in the NGF expression among 4 groups.
- 5) In RT-PCR, the HV group showed the significantly higher expression of NGF ($p=0.001$) and TRPV1 ($p=0.03$) mRNA in the mucosa than the SV group ($p=0.001$), whereas the HN group showed the significantly lower expression of NGF ($p=0.007$) and TRPV1 ($p=0.02$) than the HV group. There was no significant difference in BDNF expression in the mucosa among 4 groups. In the detrusor, the HV group showed the significantly higher expression of NGF ($p=0.03$) and BDNF ($p=0.02$) mRNA than the SV group while HN group did not show significant differences compared to the HV group. There was no significant difference in the expression of TRPV1 in the detrusor among 4 groups.

Fig.1




Fig.2




Fig.3





Fig.4



Interpretation of results

These results indicate that; (1) intravesical hydrogen peroxide instillation, which induces bladder inflammation up to 7 days after the instillation, elicit frequent urination shown by reduced ICI, and enhanced bladder pain sensitivity shown by increased freezing behaviour, which are associated with increased expression of NGF mRNA and protein as well as TRPV1 mRNA in the bladder mucosa and bladder afferent pathways and (2) intravesical liposome-based NGF antisense therapy induces a reduction in the NGF mRNA and protein expression in the bladder mucosa and bladder afferent pathways, which results in the improvement of bladder pain behaviour and frequent urination induced by hydrogen peroxide-induced chronic cystitis.

Concluding message

Intravesical liposome-based NGF antisense therapy could be a novel treatment that can avoid systemic adverse events for hypersensitive bladder disorders such as IC/BPS, in which NGF has been implicated as an important mediator for inducing afferent sensitization.

References

1. Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. *The Journal of urology* 2011 May;185(5):1716-21.
2. Kashyap M, Kawamori N, Tyagi V, Sugino Y, Chancellor M, Yoshimura N, et al. Down-regulation of nerve growth factor expression in the bladder by antisense oligonucleotides as new treatment for overactive bladder. *The Journal of urology* 2013 Aug;190(2):757-64.

Disclosures

Funding: Department of Defense (W81XWH-12-1-0565), National Institutes of Health (DK088836 and P01DK093424), **Clinical Trial:** No **Subjects:** ANIMAL **Species:** rat **Ethics Committee:** the Institutional Animal Care and Use Committee